Background	Background	NN	B-NP
Plasminogen	Plasminogen	NN	I-NP
activator	activator	NN	I-NP
inhibitor-1	inhibitor-1	NN	I-NP
(	(	-LRB-	0
PAI-1	PAI-1	NNP	B-NP
)	)	-RRB-	0
is	is	VBZ	0
a	a	DT	0
serine	serine	JJ	B-NP
proteinase	proteinase	JJ	I-NP
inhibitor	inhibitor	NN	I-NP
in	in	IN	0
the	the	DT	0
serpin	serpin	JJ	0
superfamily	superfamily	NNS	0
[	[	-LRB-	0
1	1	CD	0
2	2	CD	0
3	3	CD	0
]	]	-RRB-	0
.	.	.	0
This	This	DT	0
50	50	CD	0
kDa	kDa	JJ	B-NP
glycoprotein	glycoprotein	NN	I-NP
is	is	VBZ	0
apparently	apparently	RB	0
the	the	DT	0
most	most	RBS	0
important	important	JJ	0
plasminogen	plasminogen	JJ	B-NP
activator	activator	NNS	I-NP
tissue-type	tissue-type	JJ	I-NP
physiological	physiological	JJ	I-NP
inhibitor	inhibitor	NN	I-NP
(	(	-LRB-	0
tPA	tPA	NNP	B-NP
)	)	-RRB-	0
and	and	CC	0
of	of	IN	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
(	(	-LRB-	0
uPA	uPA	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
[	[	-LRB-	0
4	4	LS	0
]	]	-RRB-	0
It	It	PRP	0
was	was	VBD	0
shown	shown	VBN	0
to	to	TO	0
play	play	VB	0
a	a	DT	0
crucial	crucial	JJ	0
role	role	NN	0
in	in	IN	0
the	the	DT	0
regulation	regulation	NN	0
of	of	IN	0
vascular	vascular	JJ	B-NP
thrombosis	thrombosis	NN	I-NP
,	,	,	0
tumor	tumor	NN	B-NP
invasion	invasion	NN	I-NP
,	,	,	0
neovascularization	neovascularization	NN	B-NP
,	,	,	0
inflammation	inflammation	NN	B-NP
and	and	CC	0
wound	wound	VBD	0
healing.	healing.	CD	0
[	[	-LRB-	0
5	5	CD	0
6	6	CD	0
]	]	-RRB-	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
increased	increased	VBN	I-NP
plasma	plasma	JJ	I-NP
level	level	JJ	I-NP
were	were	VBD	0
found	found	VBN	0
to	to	TO	0
be	be	VB	0
correlated	correlated	VBN	0
with	with	IN	0
an	an	DT	0
increased	increased	JJ	0
risk	risk	NN	0
for	for	IN	0
cardiovascular	cardiovascular	JJ	B-NP
disease	disease	NN	I-NP
[	[	-LRB-	0
6	6	CD	0
7	7	CD	0
8	8	CD	0
]	]	-RRB-	0
The	The	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
essential	essential	JJ	I-NP
function	function	NN	I-NP
in	in	IN	0
the	the	DT	0
fibrinolytic	fibrinolytic	JJ	B-NP
system	system	NN	I-NP
has	has	VBZ	0
been	been	VBN	0
confirmed	confirmed	VBN	0
by	by	IN	0
studies	studies	NNS	0
with	with	IN	0
transgenic	transgenic	CD	B-NP
animal	animal	NN	I-NP
[	[	-LRB-	0
7	7	CD	0
9	9	CD	0
]	]	-RRB-	0
pai-1	pai-1	NN	B-NP
share	share	NN	I-NP
a	a	DT	0
35	35	CD	0
%	%	NN	0
homology	homology	NN	B-NP
with	with	IN	0
40	40	CD	0
other	other	JJ	0
serpin	serpin	NN	B-NP
[	[	-LRB-	0
10	10	CD	0
]	]	-RRB-	0
The	The	DT	0
X-ray	X-ray	NN	B-NP
structure	structure	NN	I-NP
of	of	IN	0
active	active	JJ	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
[	[	-LRB-	0
11	11	CD	0
12	12	CD	0
]	]	-RRB-	0
consists	consists	VBZ	0
of	of	IN	0
three	three	CD	0
sheets	sheets	NNS	0
(	(	-LRB-	0
A-C	A-C	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
nine	nine	CD	0
helice	helice	NN	B-NP
(	(	-LRB-	0
a-i	a-i	NNP	B-NP
)	)	-RRB-	0
and	and	CC	0
a	a	DT	0
reactive	reactive	JJ	B-NP
center	center	NN	I-NP
loop	loop	NN	I-NP
(	(	-LRB-	0
RCL	RCL	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
RCL	RCL	NNP	B-NP
contains	contains	VBZ	0
the	the	DT	0
residues	residues	JJ	0
Ser331	Ser331	NN	B-NP
to	to	TO	0
Arg356	Arg356	CD	B-NP
(	(	-LRB-	0
P16-P10	P16-P10	NNP	B-NP
'	'	POS	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
within	within	IN	0
it	it	PRP	0
there	there	EX	0
is	is	VBZ	0
a	a	DT	0
peptide	peptide	JJ	B-NP
loop	loop	NN	I-NP
(	(	-LRB-	0
Glu	Glu	NNP	B-NP
351	351	CD	0
to	to	TO	0
Pro	Pro	NNP	0
357	357	CD	0
,	,	,	0
P5	P5	NNP	B-NP
'	'	POS	I-NP
-P11	-P11	NNP	I-NP
'	'	POS	0
)	)	-RRB-	0
,	,	,	0
which	which	WDT	0
is	is	VBZ	0
defined	defined	VBN	0
as	as	IN	0
the	the	DT	0
distal	distal	JJ	B-NP
hinge	hinge	NN	I-NP
(	(	-LRB-	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
It	It	PRP	0
should	should	MD	0
be	be	VB	0
noted	noted	VBN	0
that	that	IN	0
the	the	DT	0
placement	placement	NN	0
and	and	CC	0
rcl	rcl	NN	B-NP
conformation	conformation	NN	I-NP
in	in	IN	0
active	active	JJ	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
is	is	VBZ	0
quite	quite	RB	0
different	different	JJ	0
from	from	IN	0
that	that	DT	0
of	of	IN	0
latent	latent	CD	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
[	[	-LRB-	0
13	13	CD	0
]	]	-RRB-	0
The	The	DT	0
movement	movement	NN	0
of	of	IN	0
the	the	DT	0
distal	distal	JJ	B-NP
hinge	hinge	NN	I-NP
and	and	CC	0
the	the	DT	0
insertion	insertion	NN	0
of	of	IN	0
the	the	DT	0
RCL	RCL	NNP	B-NP
into	into	IN	0
sheet	sheet	NN	0
A	A	NN	0
as	as	IN	0
strand	strand	CD	B-NP
4A	4A	CD	I-NP
(	(	-LRB-	0
s4A	s4A	NNP	B-NP
)	)	-RRB-	0
should	should	MD	0
take	take	VB	0
place	place	NN	0
during	during	IN	0
the	the	DT	0
transition	transition	NN	0
from	from	IN	0
the	the	DT	0
active	active	JJ	0
into	into	IN	0
the	the	DT	0
latent	latent	JJ	0
form	form	NN	0
of	of	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
.	.	.	0
The	The	DT	0
catalytic	catalytic	JJ	B-NP
center	center	NN	I-NP
of	of	IN	0
tPA	tPA	JJ	0
interacts	interacts	NN	0
with	with	IN	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
reactive	reactive	JJ	I-NP
site	site	NN	I-NP
with	with	IN	0
concominant	concominant	JJ	B-NP
formation	formation	NN	I-NP
of	of	IN	0
1	1	CD	0
:	:	:	0
1	1	CD	0
molar	molar	NN	B-NP
,	,	,	0
SDS-stable	SDS-stable	JJ	B-NP
complex	complex	NN	I-NP
.	.	.	0
The	The	DT	0
P1	P1	NNP	0
(	(	-LRB-	0
Arg346	Arg346	NNP	B-NP
)	)	-RRB-	0
residue	residue	NN	0
in	in	IN	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
rcl	rcl	NN	I-NP
is	is	VBZ	0
an	an	DT	0
essential	essential	JJ	B-NP
determinant	determinant	NN	I-NP
for	for	IN	0
its	its	PRP$	0
target	target	NN	B-NP
specificity	specificity	NN	I-NP
and	and	CC	0
inhibitory	inhibitory	CD	B-NP
activity.	activity.	CD	I-NP
[	[	-LRB-	0
14	14	CD	0
15	15	CD	0
]	]	-RRB-	0
Since	Since	IN	0
many	many	JJ	0
serpin	serpin	NN	B-NP
with	with	IN	0
identical	identical	JJ	0
amino	amino	JJ	0
acid	acid	NN	0
residue	residue	NN	0
at	at	IN	0
P1	P1	CD	B-NP
position	position	NN	I-NP
display	display	NN	I-NP
different	different	JJ	0
specificities	specificities	NN	0
,	,	,	0
it	it	PRP	0
is	is	VBZ	0
unlikely	unlikely	JJ	0
that	that	IN	0
the	the	DT	0
P1	P1	JJ	B-NP
residue	residue	NN	I-NP
is	is	VBZ	0
the	the	DT	0
sole	sole	JJ	0
target	target	NN	B-NP
protease	protease	NN	I-NP
specificity	specificity	NN	I-NP
determinant	determinant	NN	I-NP
,	,	,	0
other	other	JJ	0
regions	regions	NNS	0
of	of	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
may	may	MD	0
also	also	RB	0
affect	affect	VB	0
its	its	PRP$	0
specificity	specificity	NN	0
toward	toward	IN	0
target	target	NN	B-NP
protea	protea	NN	I-NP
.	.	.	0
The	The	DT	0
variable	variable	JJ	0
region	region	NN	0
in	in	IN	0
serine	serine	JJ	B-NP
proteases	proteases	JJ	I-NP
domain	domain	NN	I-NP
determines	determines	VBZ	0
their	their	PRP$	0
specificity	specificity	NN	0
for	for	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
.	.	.	0
Alignment	Alignment	NNP	0
of	of	IN	0
variable	variable	JJ	0
region	region	NN	0
1	1	CD	0
of	of	IN	0
the	the	DT	0
serine	serine	JJ	B-NP
protea	protea	NN	I-NP
shows	shows	VBZ	0
a	a	DT	0
remarkable	remarkable	JJ	0
correlation	correlation	NN	0
between	between	IN	0
the	the	DT	0
composition	composition	NN	0
of	of	IN	0
this	this	DT	0
area	area	NN	0
and	and	CC	0
their	their	PRP$	0
susceptibility	susceptibility	NN	0
to	to	TO	0
inhibition	inhibition	VB	0
by	by	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
Table	Table	NNP	0
2.	2.	NNP	0
[	[	-LRB-	0
16	16	CD	0
]	]	-RRB-	0
Both	Both	DT	0
tPA	tPA	JJ	0
and	and	CC	0
uPA	uPA	JJ	0
,	,	,	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
target	target	NN	I-NP
protea	protea	NN	I-NP
,	,	,	0
contain	contain	VBP	0
a	a	DT	0
relatively	relatively	RB	0
extensive	extensive	JJ	B-NP
variable	variable	JJ	I-NP
region	region	NN	I-NP
1	1	CD	0
,	,	,	0
consisting	consisting	VBG	0
of	of	IN	0
four	four	CD	0
to	to	TO	0
five	five	CD	0
positively	positively	RB	0
charged	charged	VBN	0
amino	amino	JJ	0
acid	acid	NN	0
residues	residues	NN	0
present	present	NN	0
at	at	IN	0
identical	identical	JJ	0
position	position	NN	0
.	.	.	0
Plasmin	Plasmin	NNP	B-NP
and	and	CC	0
thrombin	thrombin	NN	B-NP
with	with	IN	0
moderate	moderate	JJ	0
reactivity	reactivity	NN	B-NP
toward	toward	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
have	have	VBP	0
relatively	relatively	RB	0
short	short	JJ	0
variable	variable	JJ	0
regions	regions	NNS	0
which	which	WDT	0
contain	contain	VBP	0
only	only	RB	0
two	two	CD	0
to	to	TO	0
three	three	CD	0
positively	positively	RB	0
charged	charged	VBN	0
residues	residues	NNS	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
positively	positively	RB	0
charged	charged	VBN	0
amino	amino	JJ	0
acids	acids	NNS	0
in	in	IN	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
of	of	IN	0
type	type	NN	B-NP
plasminogen	plasminogen	NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
activator	activator	NN	I-NP
,	,	,	0
uPA	uPA	JJ	0
and	and	CC	0
thrombin	thrombin	NN	B-NP
play	play	VBP	0
dominant	dominant	JJ	0
roles	roles	NNS	0
in	in	IN	0
the	the	DT	0
specific	specific	JJ	0
interaction	interaction	NN	0
with	with	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
[	[	-LRB-	0
17	17	CD	0
18	18	CD	0
19	19	CD	0
]	]	-RRB-	0
Furthermore	Furthermore	RB	0
,	,	,	0
Glu350	Glu350	NNP	B-NP
(	(	-LRB-	0
P4	P4	NNP	0
'	'	POS	0
)	)	-RRB-	0
of	of	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
has	has	VBZ	0
been	been	VBN	0
shown	shown	VBN	0
to	to	TO	0
mediate	mediate	VB	0
the	the	DT	0
interaction	interaction	NN	B-NP
with	with	IN	0
type	type	NN	B-NP
plasminogen	plasminogen	NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
activator	activator	NN	I-NP
[	[	-LRB-	0
18	18	CD	0
]	]	-RRB-	0
In	In	IN	0
this	this	DT	0
study	study	NN	0
,	,	,	0
By	By	IN	0
producing	producing	VBG	B-NP
wtPAI-1	wtPAI-1	NNP	I-NP
and	and	CC	0
several	several	JJ	0
single	single	JJ	0
site	site	NN	0
mutations	mutations	NNS	0
in	in	IN	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
distal	distal	JJ	I-NP
hinge	hinge	NN	I-NP
in	in	IN	0
a	a	DT	0
baculovirus	baculovirus	JJ	B-NP
expression	expression	NN	I-NP
system	system	NN	I-NP
,	,	,	0
we	we	PRP	0
were	were	VBD	0
able	able	JJ	0
to	to	TO	0
find	find	VB	0
out	out	RP	0
the	the	DT	0
role	role	NN	0
of	of	IN	0
the	the	DT	0
distal	distal	JJ	B-NP
hinge	hinge	NN	I-NP
in	in	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
conformational	conformational	JJ	I-NP
transition	transition	NN	I-NP
and	and	CC	0
to	to	TO	0
elucidate	elucidate	VB	0
the	the	DT	0
role	role	NN	0
of	of	IN	0
Glu351	Glu351	CD	B-NP
in	in	IN	0
serine	serine	JJ	B-NP
protease	protease	JJ	I-NP
specificity	specificity	NN	I-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
.	.	.	0
Results	Results	NNP	0
wtpai-1	wtpai-1	NN	B-NP
characterization	characterization	NN	I-NP
To	To	TO	0
confirm	confirm	VB	0
the	the	DT	0
validity	validity	NN	0
of	of	IN	0
recombinant	recombinant	JJ	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
as	as	IN	0
a	a	DT	0
model	model	NN	0
to	to	TO	0
study	study	VB	0
the	the	DT	0
native	native	JJ	0
inhibitor	inhibitor	JJ	B-NP
secreted	secreted	NN	I-NP
from	from	IN	0
human	human	JJ	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
cell	cell	NN	I-NP
,	,	,	0
we	we	PRP	0
compared	compared	VBD	0
the	the	DT	0
recombinant	recombinant	JJ	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
and	and	CC	0
the	the	DT	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
PAI-1	PAI-1	CD	I-NP
first	first	JJ	0
by	by	IN	0
SDS-PAGE	SDS-PAGE	JJ	B-NP
and	and	CC	0
immunoblot	immunoblot	NN	B-NP
with	with	IN	0
anti-pai-1	anti-pai-1	NN	B-NP
monoclonal	monoclonal	CD	I-NP
antibody	antibody	NN	I-NP
.	.	.	0
The	The	DT	0
wtpai-1	wtpai-1	NN	B-NP
molecular	molecular	JJ	I-NP
weight	weight	NN	I-NP
was	was	VBD	0
found	found	VBN	0
to	to	TO	0
be	be	VB	0
lower	lower	JJR	0
than	than	IN	0
native	native	JJ	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
(	(	-LRB-	0
~50	~50	NNP	0
kDa	kDa	NNP	B-NP
,	,	,	0
Fig.	Fig.	CD	0
1B	1B	CD	0
)	)	-RRB-	0
.	.	.	0
We	We	PRP	0
assumed	assumed	VBD	0
that	that	IN	0
this	this	DT	0
is	is	VBZ	0
due	due	JJ	0
to	to	TO	0
a	a	DT	0
lower	lower	JJR	0
(	(	-LRB-	0
probably	probably	RB	0
different	different	JJ	0
)	)	-RRB-	0
extent	extent	NN	0
of	of	IN	0
glycosylation	glycosylation	NN	B-NP
in	in	IN	0
the	the	DT	0
baculovirus	baculovirus	JJ	B-NP
expression	expression	NN	I-NP
system	system	NN	I-NP
.	.	.	0
Indeed	Indeed	RB	0
,	,	,	0
when	when	WRB	0
both	both	DT	0
proteins	proteins	NNS	0
were	were	VBD	0
deglycosylated	deglycosylated	VBN	0
with	with	IN	0
N-glycanase	N-glycanase	JJ	B-NP
they	they	PRP	0
were	were	VBD	0
found	found	VBN	0
to	to	TO	0
have	have	VB	0
an	an	DT	0
essentially	essentially	RB	0
identical	identical	JJ	0
M.W.	M.W.	NNP	B-NP
(	(	-LRB-	0
~48	~48	NNP	0
kDa	kDa	NNP	B-NP
)	)	-RRB-	0
and	and	CC	0
to	to	TO	0
cross-react	cross-react	JJ	0
immunochemically	immunochemically	NNS	0
(	(	-LRB-	0
Fig.	Fig.	NNP	0
1B	1B	NNP	0
)	)	-RRB-	0
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
when	when	WRB	0
this	this	DT	0
wtPAI-1	wtPAI-1	NNP	B-NP
was	was	VBD	0
chromatographed	chromatographed	VBN	0
on	on	IN	0
heparin-Sepharose	heparin-Sepharose	JJ	B-NP
it	it	PRP	0
was	was	VBD	0
found	found	VBN	0
to	to	TO	0
be	be	VB	0
>	>	CD	0
98	98	CD	0
%	%	NN	0
pure	pure	NN	0
by	by	IN	0
silver	silver	JJ	0
staining	staining	NN	0
of	of	IN	0
the	the	DT	0
gel	gel	NN	B-NP
(	(	-LRB-	0
Fig.	Fig.	CD	0
1Alane	1Alane	CD	0
2	2	CD	0
)	)	-RRB-	0
.	.	.	0
Interestingly	Interestingly	RB	0
,	,	,	0
the	the	DT	0
specific	specific	JJ	0
wtpai	wtpai	NN	B-NP
inhibitory	inhibitory	JJ	I-NP
activity	activity	NN	I-NP
was	was	VBD	0
63	63	CD	0
±	±	CD	0
15	15	CD	0
U	U	NNP	B-NP
/	/	NNP	I-NP
ug	ug	VBD	I-NP
just	just	RB	0
after	after	IN	0
purification	purification	NN	B-NP
,	,	,	0
and	and	CC	0
was	was	VBD	0
increased	increased	VBN	0
to	to	TO	0
84	84	CD	0
±	±	CD	0
21	21	CD	0
U	U	NNP	B-NP
/	/	NNP	I-NP
ug	ug	NN	I-NP
after	after	IN	0
denatured	denatured	NN	0
by	by	IN	0
6	6	CD	0
M	M	NNP	0
guanidine	guanidine	NN	B-NP
hydrochloride	hydrochloride	NN	I-NP
and	and	CC	0
refolded	refolded	NN	B-NP
in	in	IN	0
50	50	CD	0
mM	mM	JJ	B-NP
sodium	sodium	NN	I-NP
acetate	acetate	NN	I-NP
(	(	-LRB-	0
pH	pH	NNP	B-NP
5.6	5.6	CD	0
)	)	-RRB-	0
at	at	IN	0
4°C	4°C	CD	0
.	.	.	0
In	In	IN	0
contrast	contrast	NN	0
,	,	,	0
the	the	DT	0
specific	specific	JJ	0
activity	activity	NN	0
of	of	IN	0
the	the	DT	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
PAI-1	PAI-1	NN	I-NP
was	was	VBD	0
only	only	RB	0
5	5	CD	0
±	±	CD	0
3	3	CD	0
U	U	NNP	B-NP
/	/	NNP	I-NP
ug	ug	NN	I-NP
before	before	IN	0
activation	activation	NN	B-NP
,	,	,	0
and	and	CC	0
was	was	VBD	0
only	only	RB	0
increased	increased	VBN	0
to	to	TO	0
45	45	CD	0
±	±	CD	0
16	16	CD	0
U	U	NNP	B-NP
/	/	NNP	I-NP
μg	μg	NN	I-NP
after	after	IN	0
denaturing	denaturing	NN	B-NP
and	and	CC	0
refolding	refolding	NN	B-NP
.	.	.	0
The	The	DT	0
high	high	JJ	0
specific	specific	JJ	0
wt-pai-1	wt-pai-1	NN	B-NP
inhibitory	inhibitory	JJ	I-NP
activity	activity	NN	I-NP
could	could	MD	0
be	be	VB	0
due	due	JJ	0
to	to	TO	0
the	the	DT	0
fact	fact	NN	0
that	that	IN	0
it	it	PRP	0
was	was	VBD	0
secreted	secreted	VBN	0
from	from	IN	0
insect	insect	CD	B-NP
high-5	high-5	NN	I-NP
cell	cell	NN	I-NP
cultured	cultured	VBN	0
at	at	IN	0
27°C	27°C	NNP	0
,	,	,	0
while	while	IN	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
fibrosarcoma	fibrosarcoma	JJ	I-NP
preparation	preparation	NN	I-NP
was	was	VBD	0
obtained	obtained	VBN	0
from	from	IN	0
the	the	DT	0
medium	medium	NN	0
of	of	IN	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
cell	cell	NN	I-NP
cultured	cultured	VBN	0
at	at	IN	0
37°C	37°C	NNP	0
[	[	-LRB-	0
20	20	CD	0
]	]	-RRB-	0
.	.	.	0
Exposure	Exposure	NN	0
to	to	TO	0
the	the	DT	0
higher	higher	JJR	0
temperature	temperature	NN	0
could	could	MD	0
accelerate	accelerate	VB	0
the	the	DT	0
conversion	conversion	NN	0
of	of	IN	0
the	the	DT	0
inhibitor	inhibitor	NN	0
into	into	IN	0
its	its	PRP$	0
latent	latent	JJ	0
form	form	NN	0
.	.	.	0
The	The	DT	0
wtpai-1	wtpai-1	NN	B-NP
functional	functional	JJ	I-NP
stability	stability	NN	I-NP
and	and	CC	0
the	the	DT	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
PAI-1	PAI-1	NN	I-NP
in	in	IN	0
the	the	DT	0
absence	absence	NN	B-NP
or	or	CC	0
in	in	IN	0
presence	presence	NN	0
of	of	IN	0
vitronectin	vitronectin	NN	B-NP
are	are	VBP	0
illustrated	illustrated	VBN	0
in	in	IN	0
Figure	Figure	NNP	0
1C.	1C.	NNP	0
wtPAI-1	wtPAI-1	NNP	B-NP
lost	lost	VBD	0
its	its	PRP$	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
at	at	IN	0
the	the	DT	0
same	same	JJ	0
pace	pace	NN	0
as	as	IN	0
the	the	DT	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
PAI-1	PAI-1	NN	I-NP
,	,	,	0
indicating	indicating	VBG	0
that	that	IN	0
its	its	PRP$	0
functional	functional	JJ	B-NP
half	half	NN	I-NP
life	life	NN	I-NP
as	as	IN	0
an	an	DT	0
inhibitor	inhibitor	NN	0
and	and	CC	0
its	its	PRP$	0
ability	ability	NN	B-NP
to	to	TO	0
be	be	VB	0
stabilized	stabilized	VBN	0
by	by	IN	0
vitronectin	vitronectin	NN	B-NP
are	are	VBP	0
similar	similar	JJ	0
to	to	TO	0
those	those	DT	0
of	of	IN	0
the	the	DT	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
PAI-1	PAI-1	NN	I-NP
.	.	.	0
The	The	DT	0
second-order	second-order	JJ	B-NP
rate	rate	NN	I-NP
constant	constant	JJ	I-NP
(	(	-LRB-	0
in	in	IN	0
M	M	NNP	0
-1s	-1s	NNP	0
-1units	-1units	NNP	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
PAI-1	PAI-1	NN	I-NP
and	and	CC	0
the	the	DT	0
wtPAI-1	wtPAI-1	NN	B-NP
towards	towards	IN	0
t-PA	t-PA	NNP	B-NP
were	were	VBD	0
1.4	1.4	CD	0
±	±	CD	0
0.5	0.5	CD	0
×	×	CD	0
10	10	CD	0
7and	7and	CD	0
1.7	1.7	CD	0
±	±	CD	0
0.6	0.6	CD	0
×	×	CD	0
10	10	CD	0
7	7	CD	0
,	,	,	0
and	and	CC	0
towards	towards	IN	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
were	were	VBD	0
4.1	4.1	CD	0
±	±	CD	0
1.4	1.4	CD	0
×	×	CD	0
10	10	CD	0
7and	7and	CD	0
4.4	4.4	CD	0
±	±	CD	0
1.6	1.6	CD	0
×	×	CD	0
10	10	CD	0
7	7	CD	0
,	,	,	0
respectively	respectively	RB	0
.	.	.	0
These	These	DT	0
results	results	NNS	0
show	show	VBP	0
that	that	IN	0
the	the	DT	0
wtPAI-1	wtPAI-1	NNP	B-NP
could	could	MD	0
inhibit	inhibit	VB	0
tPA	tPA	JJ	0
or	or	CC	0
uPA	uPA	JJ	0
at	at	IN	0
the	the	DT	0
same	same	JJ	0
rate	rate	NN	0
as	as	IN	0
the	the	DT	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
PAI-1	PAI-1	NN	I-NP
.	.	.	0
In	In	IN	0
addition	addition	NN	B-NP
,	,	,	0
it	it	PRP	0
is	is	VBZ	0
known	known	VBN	0
that	that	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
inhibits	inhibits	NNS	0
either	either	CC	0
tPA	tPA	JJ	0
or	or	CC	0
uPA	uPA	JJ	0
by	by	IN	0
forming	forming	VBG	0
a	a	DT	0
1	1	CD	0
:	:	:	0
1	1	CD	0
SDS	SDS	JJ	B-NP
stable	stable	JJ	I-NP
complex	complex	NN	I-NP
[	[	-LRB-	0
4	4	LS	0
]	]	-RRB-	0
,	,	,	0
wtPAI-1	wtPAI-1	NNP	B-NP
indeed	indeed	RB	0
could	could	MD	0
form	form	VB	0
SDS	SDS	JJ	B-NP
stable	stable	JJ	I-NP
complex	complex	NN	I-NP
with	with	IN	0
tPA	tPA	JJ	0
or	or	CC	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
(	(	-LRB-	0
Fig.	Fig.	NNP	0
3A	3A	NNP	0
)	)	-RRB-	0
just	just	RB	0
as	as	IN	0
fibrosarcoma	fibrosarcoma	CD	B-NP
PAI-1	PAI-1	CD	I-NP
.	.	.	0
single	single	JJ	B-NP
site	site	NN	I-NP
mutation	mutation	NN	I-NP
within	within	IN	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
distal	distal	JJ	I-NP
hinge	hinge	NN	I-NP
Since	Since	IN	0
a	a	DT	0
proline	proline	NN	B-NP
occurs	occurs	VBZ	0
not	not	RB	0
only	only	RB	0
in	in	IN	0
position	position	NN	0
357	357	CD	0
of	of	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
,	,	,	0
but	but	CC	0
also	also	RB	0
in	in	IN	0
the	the	DT	0
corresponding	corresponding	JJ	0
position	position	NN	0
of	of	IN	0
several	several	JJ	0
other	other	JJ	0
serpin	serpin	NN	B-NP
(	(	-LRB-	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
we	we	PRP	0
attempted	attempted	VBD	0
to	to	TO	0
find	find	VB	0
out	out	RP	0
how	how	WRB	0
does	does	VBZ	0
a	a	DT	0
mutation	mutation	NN	0
of	of	IN	0
P357	P357	RB	0
affect	affect	VB	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
inhibitory	inhibitory	JJ	I-NP
activity	activity	NN	I-NP
.	.	.	0
Mutant	Mutant	NNP	B-NP
of	of	IN	0
Pro357Gly	Pro357Gly	NNP	0
blocked	blocked	VBD	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
inhibitory	inhibitory	JJ	I-NP
activity	activity	NN	I-NP
(	(	-LRB-	0
Fig.	Fig.	NNP	0
2A	2A	NNP	0
)	)	-RRB-	0
.	.	.	0
Similarly	Similarly	RB	0
,	,	,	0
a	a	DT	0
mutation	mutation	NN	0
into	into	IN	0
proline	proline	NN	B-NP
of	of	IN	0
either	either	DT	0
Asp355	Asp355	NNP	B-NP
or	or	CC	0
Arg356	Arg356	NNP	B-NP
also	also	RB	0
inactivated	inactivated	VB	0
the	the	DT	0
inhibitor	inhibitor	NN	0
.	.	.	0
It	It	PRP	0
should	should	MD	0
be	be	VB	0
noted	noted	VBN	0
that	that	IN	0
all	all	PDT	0
these	these	DT	0
mutant	mutant	NN	B-NP
could	could	MD	0
be	be	VB	0
activated	activated	VBN	0
to	to	TO	0
a	a	DT	0
similar	similar	JJ	0
extent	extent	NN	0
by	by	IN	0
6	6	CD	0
M	M	NNP	0
Gnd-HCl	Gnd-HCl	NNP	B-NP
(	(	-LRB-	0
~20	~20	NNP	0
%	%	NN	0
wtpai-1	wtpai-1	NN	B-NP
inhibitory	inhibitory	NN	I-NP
activity	activity	NN	I-NP
,	,	,	0
activated	activated	VBN	0
under	under	IN	0
the	the	DT	0
same	same	JJ	0
conditions	conditions	NNS	0
)	)	-RRB-	0
.	.	.	0
These	These	DT	0
results	results	NNS	0
suggest	suggest	VBP	0
that	that	IN	0
a	a	DT	0
single	single	JJ	0
site	site	NN	0
mutation	mutation	NN	0
at	at	IN	0
either	either	DT	0
one	one	NN	0
of	of	IN	0
the	the	DT	0
positions	positions	NNS	0
355	355	CD	0
,	,	,	0
356	356	CD	0
or	or	CC	0
357	357	CD	0
significantly	significantly	RB	0
inactivates	inactivates	JJ	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
.	.	.	0
To	To	TO	0
elucidate	elucidate	VB	0
the	the	DT	0
mechanism	mechanism	NN	0
through	through	IN	0
which	which	WDT	0
such	such	JJ	0
mutations	mutations	NNS	0
affect	affect	VBP	0
the	the	DT	0
activity	activity	NN	0
of	of	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
,	,	,	0
we	we	PRP	0
determined	determined	VBD	0
their	their	PRP$	0
effect	effect	NN	0
on	on	IN	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
functional	functional	JJ	I-NP
stability	stability	NN	I-NP
and	and	CC	0
on	on	IN	0
its	its	PRP$	0
ability	ability	NN	B-NP
to	to	TO	0
form	form	VB	0
an	an	DT	0
sd	sd	NN	B-NP
stable	stable	JJ	0
complex	complex	NN	0
with	with	IN	0
either	either	DT	0
tPA	tPA	JJ	0
or	or	CC	0
uPA	uPA	JJ	0
.	.	.	0
As	As	RB	0
seen	seen	VBN	0
in	in	IN	0
Fig.	Fig.	CD	0
2B	2B	CD	0
,	,	,	0
the	the	DT	0
rate	rate	NN	0
of	of	IN	0
the	the	DT	0
spontaneous	spontaneous	JJ	B-NP
inactivation	inactivation	NN	I-NP
of	of	IN	0
the	the	DT	0
inhibitor	inhibitor	NN	0
was	was	VBD	0
significantly	significantly	RB	0
increased	increased	VBN	0
upon	upon	IN	0
mutation	mutation	NN	0
:	:	:	0
the	the	DT	0
functional	functional	JJ	B-NP
half	half	NN	I-NP
life	life	NN	I-NP
of	of	IN	0
the	the	DT	0
mutants	mutants	JJ	0
Asp355Pro	Asp355Pro	NN	0
,	,	,	0
Arg356Pro	Arg356Pro	NNP	0
and	and	CC	0
Pro357Gly	Pro357Gly	NNP	0
was	was	VBD	0
23.8	23.8	CD	0
±	±	CD	0
4.5	4.5	CD	0
min	min	NN	B-NP
,	,	,	0
26.2	26.2	CD	0
±	±	CD	0
3.7	3.7	CD	0
min	min	NN	B-NP
and	and	CC	0
24.7	24.7	CD	0
±	±	CD	0
4.8	4.8	CD	0
min	min	NN	B-NP
,	,	,	0
respectively	respectively	RB	0
,	,	,	0
while	while	IN	0
that	that	DT	0
of	of	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
was	was	VBD	0
89.8	89.8	CD	0
±	±	CD	0
8.7	8.7	CD	0
min	min	NN	B-NP
.	.	.	0
Interestingly	Interestingly	RB	0
,	,	,	0
there	there	EX	0
was	was	VBD	0
no	no	DT	0
significant	significant	JJ	0
difference	difference	NN	0
between	between	IN	0
the	the	DT	0
mutants	mutants	JJ	B-NP
tested	tested	NN	I-NP
and	and	CC	0
the	the	DT	0
wtPAI-1	wtPAI-1	NN	B-NP
in	in	IN	0
their	their	PRP$	0
ability	ability	NN	B-NP
to	to	TO	0
inactivate	inactivate	VB	0
either	either	DT	0
tPA	tPA	JJ	0
or	or	CC	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
(	(	-LRB-	0
Table	Table	NNP	0
3	3	CD	0
)	)	-RRB-	0
.	.	.	0
They	They	PRP	0
could	could	MD	0
also	also	RB	0
form	form	VB	0
sds-stable	sds-stable	NN	B-NP
complex	complex	JJ	I-NP
with	with	IN	0
tPA	tPA	JJ	0
or	or	CC	0
uPA	uPA	JJ	0
just	just	RB	0
as	as	RB	0
well	well	RB	0
as	as	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
(	(	-LRB-	0
Fig.	Fig.	NNP	0
3A	3A	NNP	0
)	)	-RRB-	0
.	.	.	0
An	An	DT	0
interesting	interesting	JJ	0
structural	structural	JJ	B-NP
similarity	similarity	NN	I-NP
among	among	IN	0
several	several	JJ	0
serpin	serpin	NN	B-NP
is	is	VBZ	0
known	known	VBN	0
to	to	TO	0
occur	occur	VB	0
at	at	IN	0
the	the	DT	0
position	position	NN	B-NP
corresponding	corresponding	NN	I-NP
to	to	TO	0
355	355	CD	0
in	in	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
.	.	.	0
While	While	IN	0
in	in	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
this	this	DT	0
position	position	NN	0
accommodates	accommodates	VBD	0
a	a	DT	0
negatively	negatively	RB	0
charged	charged	VBN	0
aspartic	aspartic	JJ	B-NP
acid	acid	NN	I-NP
residue	residue	NN	I-NP
,	,	,	0
in	in	IN	0
other	other	JJ	0
serpin	serpin	NN	B-NP
it	it	PRP	0
sometimes	sometimes	RB	0
accommodates	accommodates	VB	0
its	its	PRP$	0
charged	charged	VBN	B-NP
analog	analog	NN	I-NP
asparagine	asparagine	NN	I-NP
non	non	NN	I-NP
(	(	-LRB-	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
Asp355His	Asp355His	NNP	0
,	,	,	0
Asp355Lys	Asp355Lys	NNP	0
,	,	,	0
Asp355Glu	Asp355Glu	NNP	0
,	,	,	0
Asp355Gln	Asp355Gln	NNP	0
and	and	CC	0
Asp355Asn	Asp355Asn	NNP	0
were	were	VBD	0
prepared	prepared	VBN	0
and	and	CC	0
used	used	VBN	0
to	to	TO	0
show	show	VB	0
that	that	IN	0
the	the	DT	0
negatively	negatively	RB	0
charged	charged	VBN	0
aspartic	aspartic	JJ	B-NP
acid	acid	NN	I-NP
in	in	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
is	is	VBZ	0
essential	essential	JJ	0
(	(	-LRB-	0
though	though	RB	0
not	not	RB	0
sufficient	sufficient	JJ	0
)	)	-RRB-	0
for	for	IN	0
its	its	PRP$	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
.	.	.	0
Mutation	Mutation	NN	0
of	of	IN	0
Asp355	Asp355	CD	B-NP
by	by	IN	0
asparagina	asparagina	NN	B-NP
(	(	-LRB-	0
the	the	DT	0
non	non	NN	B-NP
charged	charged	VBD	0
analog	analog	VBN	0
of	of	IN	0
aspartic	aspartic	JJ	B-NP
acid	acid	NN	I-NP
)	)	-RRB-	0
,	,	,	0
or	or	CC	0
by	by	IN	0
histidine	histidine	NN	B-NP
or	or	CC	0
lysine	lysine	NN	B-NP
(	(	-LRB-	0
that	that	WDT	0
have	have	VBP	0
a	a	DT	0
positively	positively	RB	0
charged	charged	VBN	B-NP
side	side	NN	I-NP
chain	chain	NN	I-NP
)	)	-RRB-	0
or	or	CC	0
by	by	IN	0
alanina	alanina	NN	B-NP
(	(	-LRB-	0
neutral	neutral	LS	0
)	)	-RRB-	0
,	,	,	0
inactivated	inactivated	CD	B-NP
PAI-1	PAI-1	CD	I-NP
.	.	.	0
Replacement	Replacement	NN	0
of	of	IN	0
this	this	DT	0
aspartic	aspartic	JJ	B-NP
acid	acid	NN	I-NP
residue	residue	VBZ	I-NP
even	even	RB	0
by	by	IN	0
the	the	DT	0
negatively	negatively	RB	0
charged	charged	VBN	0
glutamic	glutamic	JJ	B-NP
acid	acid	NN	I-NP
(	(	-LRB-	0
a	a	DT	0
very	very	RB	0
close	close	VB	0
analog	analog	VBN	0
of	of	IN	0
aspartic	aspartic	JJ	B-NP
acid	acid	NN	I-NP
)	)	-RRB-	0
did	did	VBD	0
not	not	RB	0
significantly	significantly	RB	0
suffice	suffice	VB	0
to	to	TO	0
restore	restore	VB	0
a	a	DT	0
full	full	JJ	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
inhibitory	inhibitory	JJ	I-NP
activity	activity	NN	I-NP
(	(	-LRB-	0
Fig.	Fig.	NNP	0
3B	3B	NNP	0
)	)	-RRB-	0
.	.	.	0
After	After	IN	0
activation	activation	NN	B-NP
with	with	IN	0
6	6	CD	0
M	M	NNP	0
Gnd-HCl	Gnd-HCl	NNP	B-NP
,	,	,	0
each	each	DT	0
of	of	IN	0
the	the	DT	0
six	six	CD	0
mutant	mutant	NN	B-NP
exhibited	exhibited	VBP	0
a	a	DT	0
relatively	relatively	RB	0
high	high	JJ	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
,	,	,	0
but	but	CC	0
their	their	PRP$	0
specific	specific	JJ	0
activities	activities	NNS	0
were	were	VBD	0
still	still	RB	0
much	much	RB	0
lower	lower	JJR	0
than	than	IN	0
that	that	DT	0
of	of	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
(	(	-LRB-	0
Fig.	Fig.	NNP	0
3B	3B	NNP	0
)	)	-RRB-	0
.	.	.	0
Among	Among	IN	0
them	them	PRP	0
,	,	,	0
Asp355Lys	Asp355Lys	NNP	0
(	(	-LRB-	0
5.1	5.1	CD	0
±	±	CD	0
4.1	4.1	CD	0
U	U	NNP	B-NP
/	/	CD	I-NP
ug	ug	CD	I-NP
)	)	-RRB-	0
had	had	VBD	0
the	the	DT	0
lowest	lowest	JJS	0
specific	specific	JJ	0
activity	activity	NN	0
,	,	,	0
while	while	IN	0
the	the	DT	0
Asp355Asn	Asp355Asn	NNP	0
(	(	-LRB-	0
20	20	CD	0
±	±	CD	0
4.2	4.2	CD	0
U	U	NNP	B-NP
/	/	CD	I-NP
μg	μg	CD	I-NP
)	)	-RRB-	0
had	had	VBD	0
the	the	DT	0
highest	highest	JJS	0
specific	specific	JJ	0
activity	activity	NN	0
(	(	-LRB-	0
Fig.	Fig.	NNP	0
3B	3B	NNP	0
)	)	-RRB-	0
.	.	.	0
Although	Although	IN	0
they	they	PRP	0
had	had	VBD	0
lower	lower	RBR	0
specific	specific	JJ	0
activities	activities	NNS	0
,	,	,	0
all	all	DT	0
of	of	IN	0
the	the	DT	0
mutant	mutant	NN	B-NP
mentioned	mentioned	VBD	0
above	above	RB	0
could	could	MD	0
still	still	RB	0
form	form	VB	0
sds-stable	sds-stable	NN	B-NP
complex	complex	JJ	I-NP
with	with	IN	0
tPA	tPA	JJ	0
or	or	CC	0
uPA	uPA	JJ	0
just	just	RB	0
as	as	IN	0
the	the	DT	0
wtPAI-1	wtPAI-1	NNP	B-NP
(	(	-LRB-	0
data	data	NNS	0
not	not	RB	0
shown	shown	VBN	0
)	)	-RRB-	0
.	.	.	0
Two	Two	CD	0
additional	additional	JJ	0
mutations	mutations	NNS	0
,	,	,	0
Arg356Ala	Arg356Ala	NNP	0
and	and	CC	0
Arg356Glu	Arg356Glu	NNP	0
,	,	,	0
were	were	VBD	0
prepared	prepared	VBN	0
to	to	TO	0
further	further	VB	0
elucidate	elucidate	VBN	0
the	the	DT	0
role	role	NN	0
of	of	IN	0
Arg356	Arg356	CD	B-NP
.	.	.	0
The	The	DT	0
specific	specific	JJ	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
of	of	IN	0
Arg356Ala	Arg356Ala	NNP	0
was	was	VBD	0
7.2	7.2	CD	0
±	±	CD	0
2.5	2.5	CD	0
U	U	NNP	B-NP
/	/	NNP	I-NP
μg	μg	NN	I-NP
,	,	,	0
while	while	IN	0
Arg356Glu	Arg356Glu	CD	0
exhibited	exhibited	NNS	0
essentially	essentially	RB	0
no	no	DT	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
.	.	.	0
This	This	DT	0
specific	specific	JJ	0
activity	activity	NN	0
was	was	VBD	0
increased	increased	VBN	0
to	to	TO	0
35.4	35.4	CD	0
±	±	CD	0
8.7	8.7	CD	0
U	U	NNP	B-NP
/	/	NNP	I-NP
ug	ug	NN	I-NP
for	for	IN	0
Arg356Ala	Arg356Ala	NNP	0
and	and	CC	0
6.4	6.4	CD	0
±	±	CD	0
2.3	2.3	CD	0
U	U	NNP	B-NP
/	/	NNP	I-NP
μg	μg	NN	I-NP
for	for	IN	0
Arg356Glu	Arg356Glu	CD	0
after	after	IN	0
denature	denature	NN	B-NP
and	and	CC	0
refolding	refolding	NN	B-NP
.	.	.	0
Just	Just	RB	0
like	like	IN	0
ARG356Pro	ARG356Pro	NNP	0
,	,	,	0
Arg356Ala	Arg356Ala	NNP	0
and	and	CC	0
Arg356Glu	Arg356Glu	NNP	0
were	were	VBD	0
much	much	RB	0
more	more	JJR	0
labile	labile	NN	B-NP
than	than	IN	0
wtPAI-1	wtPAI-1	CD	B-NP
.	.	.	0
These	These	DT	0
results	results	NNS	0
suggest	suggest	VBP	0
that	that	IN	0
the	the	DT	0
role	role	NN	0
of	of	IN	0
the	the	DT	0
Asp355-Pro357	Asp355-Pro357	JJ	B-NP
segment	segment	NN	I-NP
is	is	VBZ	0
to	to	TO	0
stabilize	stabilize	VB	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
inhibitory	inhibitory	JJ	I-NP
conformation	conformation	NN	I-NP
.	.	.	0
Specific	Specific	JJ	0
activity	activity	NN	0
,	,	,	0
functional	functional	JJ	B-NP
stability	stability	NN	I-NP
and	and	CC	0
complex	complex	JJ	0
formation	formation	NN	0
of	of	IN	0
Glu351Ala	Glu351Ala	NNP	0
and	and	CC	0
Glu351Arg	Glu351Arg	CD	0
The	The	DT	0
specific	specific	JJ	0
wtpai-1	wtpai-1	NN	B-NP
inhibitory	inhibitory	JJ	I-NP
activity	activity	NN	I-NP
,	,	,	0
Glu351Ala	Glu351Ala	NNP	0
and	and	CC	0
Glu351Arg	Glu351Arg	NNP	0
were	were	VBD	0
assessed	assessed	VBN	0
with	with	IN	0
uPA	uPA	JJ	0
and	and	CC	0
S-2444	S-2444	NNP	B-NP
.	.	.	0
As	As	RB	0
shown	shown	VBN	0
in	in	IN	0
Fg.	Fg.	CD	B-NP
4A	4A	CD	0
,	,	,	0
the	the	DT	0
specificity	specificity	NN	0
of	of	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
Glu351Ala	Glu351Ala	NNP	0
and	and	CC	0
Glu351Arg	Glu351Arg	CD	0
after	after	IN	0
denatured	denatured	NN	0
by	by	IN	0
6	6	CD	0
M	M	NNP	0
guanidine	guanidine	NN	B-NP
hydrochloride	hydrochloride	NN	I-NP
and	and	CC	0
dialyzed	dialyzed	NN	B-NP
against	against	IN	0
50	50	CD	0
mM	mM	JJ	B-NP
sodium	sodium	JJ	I-NP
acetate	acetate	NN	I-NP
,	,	,	0
pH	pH	JJ	0
5.6	5.6	CD	0
,	,	,	0
was	was	VBD	0
84	84	CD	0
±	±	CD	0
15	15	CD	0
,	,	,	0
112	112	CD	0
±	±	CD	0
18	18	CD	0
and	and	CC	0
68	68	CD	0
±	±	CD	0
9	9	CD	0
U	U	NNP	B-NP
/	/	NNP	I-NP
ug	ug	NN	I-NP
,	,	,	0
respectively	respectively	RB	0
.	.	.	0
Glu351Ala	Glu351Ala	NNP	0
had	had	VBD	0
a	a	DT	0
higher	higher	JJR	0
,	,	,	0
and	and	CC	0
Glu351Arg	Glu351Arg	CD	0
lower	lower	JJR	0
specific	specific	JJ	0
activity	activity	NN	0
than	than	IN	0
wtPAI-1	wtPAI-1	CD	B-NP
.	.	.	0
The	The	DT	0
specific	specific	JJ	0
activities	activities	NNS	0
of	of	IN	0
PAI-1s	PAI-1s	NNP	B-NP
determined	determined	VBD	0
immediately	immediately	RB	0
after	after	IN	0
purification	purification	NN	B-NP
displayed	displayed	VBD	0
similar	similar	JJ	0
pattern	pattern	NN	0
as	as	IN	0
that	that	DT	0
of	of	IN	0
inhibitors	inhibitors	JJ	0
reactivated	reactivated	NN	0
.	.	.	0
There	There	EX	0
was	was	VBD	0
about	about	IN	0
15-20	15-20	CD	0
%	%	NN	0
increase	increase	NN	0
after	after	IN	0
reactivation	reactivation	VBG	0
compared	compared	VBN	0
to	to	TO	0
each	each	DT	0
untreated	untreated	JJ	0
protein	protein	NN	B-NP
itself	itself	PRP	0
.	.	.	0
As	As	RB	0
shown	shown	VBN	0
in	in	IN	0
Fig.	Fig.	CD	0
4B	4B	CD	0
,	,	,	0
the	the	DT	0
two	two	CD	0
mutant	mutant	NN	B-NP
also	also	RB	0
spontaneously	spontaneously	RB	0
lost	lost	VBD	0
their	their	PRP$	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
(	(	-LRB-	I-NP
convert	convert	VB	I-NP
to	to	TO	I-NP
latency	latency	CD	I-NP
)	)	-RRB-	I-NP
as	as	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
but	but	CC	0
at	at	IN	0
different	different	JJ	0
rates	rates	NNS	0
.	.	.	0
The	The	DT	0
wtpai-1	wtpai-1	NN	B-NP
functional	functional	JJ	I-NP
stability	stability	NN	I-NP
,	,	,	0
Glu351Ala	Glu351Ala	NNP	0
,	,	,	0
Glu351Arg	Glu351Arg	NNP	0
was	was	VBD	0
about	about	IN	0
18	18	CD	0
±	±	CD	0
5	5	CD	0
,	,	,	0
90	90	CD	0
±	±	CD	0
8	8	CD	0
and	and	CC	0
14	14	CD	0
±	±	CD	0
3	3	CD	0
minutes	minutes	NNS	0
,	,	,	0
respectively	respectively	RB	0
.	.	.	0
It	It	PRP	0
suggested	suggested	VBD	0
that	that	IN	0
the	the	DT	0
specific	specific	JJ	0
activities	activities	NNS	0
measured	measured	VBN	0
above	above	IN	0
,	,	,	0
to	to	TO	0
some	some	DT	0
extent	extent	NN	0
,	,	,	0
proportionally	proportionally	RB	0
represent	represent	VB	0
the	the	DT	0
functional	functional	JJ	B-NP
stability	stability	NN	I-NP
.	.	.	0
More	More	RBR	0
importantly	importantly	RB	0
,	,	,	0
amount	amount	NN	B-NP
complex	complex	JJ	I-NP
formed	formed	VBN	0
by	by	IN	0
tPA	tPA	JJ	0
and	and	CC	0
PAI-1s	PAI-1s	NNP	B-NP
remained	remained	VBD	0
after	after	IN	0
incubation	incubation	NN	0
at	at	IN	0
37°C	37°C	NNP	0
(	(	-LRB-	0
Fig.	Fig.	NNP	0
4C	4C	NNP	0
)	)	-RRB-	0
were	were	VBD	0
proportionally	proportionally	JJ	0
concordant	concordant	NN	0
with	with	IN	0
the	the	DT	0
results	results	NNS	0
obtained	obtained	VBN	0
from	from	IN	0
enzymatic	enzymatic	JJ	B-NP
stability	stability	NN	I-NP
assay	assay	NN	I-NP
(	(	-LRB-	0
Fig.	Fig.	NNP	0
4B	4B	NNP	0
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
proves	proves	NN	0
that	that	IN	0
results	results	NNS	0
from	from	IN	0
enzymatic	enzymatic	JJ	B-NP
assay	assay	NN	I-NP
are	are	VBP	0
valid	valid	JJ	0
.	.	.	0
The	The	DT	0
result	result	NN	0
of	of	IN	0
functional	functional	JJ	B-NP
stability	stability	NN	I-NP
suggests	suggests	VBZ	0
that	that	IN	0
Glu351	Glu351	NNP	B-NP
is	is	VBZ	0
indeed	indeed	RB	0
involved	involved	VBN	0
in	in	IN	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
conformational	conformational	JJ	I-NP
transition	transition	NN	I-NP
.	.	.	0
Inhibition	Inhibition	NNP	0
of	of	IN	0
thrombin	thrombin	NN	B-NP
by	by	IN	0
PAI-1s	PAI-1s	NNP	B-NP
and	and	CC	0
pai-1	pai-1	NN	B-NP
neutralization	neutralization	NN	I-NP
by	by	IN	0
Thrombin	Thrombin	NNP	B-NP
Both	Both	DT	0
mutants	mutants	JJ	B-NP
inhibited	inhibited	JJ	I-NP
thrombin	thrombin	NN	I-NP
more	more	RBR	0
efficiently	efficiently	RB	0
than	than	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
more	more	RBR	0
importantly	importantly	RB	0
,	,	,	0
Glu351Ala	Glu351Ala	NNP	0
was	was	VBD	0
better	better	JJR	0
than	than	IN	0
Glu351Arg	Glu351Arg	CD	0
in	in	IN	0
inhibiting	inhibiting	JJ	0
thrombin	thrombin	NN	B-NP
(	(	-LRB-	0
Fig.	Fig.	NNP	0
5A	5A	NNP	0
)	)	-RRB-	0
;	;	:	0
Inhibition	Inhibition	NNP	0
of	of	IN	0
thrombin	thrombin	NN	B-NP
by	by	IN	0
Glu351Arg	Glu351Arg	NNP	0
was	was	VBD	0
almost	almost	RB	0
as	as	IN	0
same	same	JJ	0
as	as	IN	0
by	by	IN	0
Glu351Ala	Glu351Ala	CD	0
in	in	IN	0
presence	presence	NN	0
of	of	IN	0
vitronectin	vitronectin	NN	B-NP
(	(	-LRB-	0
Fig.	Fig.	NNP	0
5B	5B	NNP	0
)	)	-RRB-	0
,	,	,	0
which	which	WDT	0
facilitated	facilitated	VBZ	0
the	the	DT	0
thrombin	thrombin	JJ	B-NP
inhibition	inhibition	NN	I-NP
by	by	IN	0
both	both	DT	0
mutant	mutant	NN	B-NP
.	.	.	0
When	When	WRB	0
excess	excess	JJ	0
equal	equal	JJ	0
amount	amount	NN	0
of	of	IN	0
thrombin	thrombin	NN	B-NP
was	was	VBD	0
incubated	incubated	VBN	0
with	with	IN	0
equal	equal	JJ	0
amount	amount	NN	0
of	of	IN	0
PAI-1s	PAI-1s	CD	B-NP
in	in	IN	0
term	term	NN	0
of	of	IN	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
against	against	IN	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
,	,	,	0
mutant	mutant	JJ	B-NP
inhibitor	inhibitor	NN	I-NP
were	were	VBD	0
neutralized	neutralized	VBN	0
faster	faster	RBR	0
by	by	IN	0
thrombin	thrombin	NN	B-NP
than	than	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
and	and	CC	0
vitronectin	vitronectin	VBP	0
also	also	RB	0
facilitated	facilitated	VB	0
the	the	DT	0
neutralization	neutralization	NN	B-NP
of	of	IN	0
Glu351Ala	Glu351Ala	NNP	0
or	or	CC	0
Glu351Arg	Glu351Arg	CD	0
by	by	IN	0
thrombin	thrombin	NN	B-NP
,	,	,	0
just	just	RB	0
similar	similar	JJ	0
to	to	TO	0
the	the	DT	0
wtPAI-1	wtPAI-1	NNP	B-NP
(	(	-LRB-	0
Fig.	Fig.	NNP	0
5C	5C	NNP	0
)	)	-RRB-	0
.	.	.	0
Inhibition	Inhibition	NNP	0
of	of	IN	0
plasmin	plasmin	NN	B-NP
by	by	IN	0
PAI-1s	PAI-1s	CD	B-NP
When	When	WRB	0
plasmin	plasmin	NN	B-NP
was	was	VBD	0
incubated	incubated	VBN	0
with	with	IN	0
increased	increased	JJ	0
amount	amount	NN	0
of	of	IN	0
equal	equal	JJ	0
active	active	JJ	0
PAI-1s	PAI-1s	NN	B-NP
in	in	IN	0
absence	absence	NN	B-NP
or	or	CC	0
in	in	IN	0
presence	presence	NN	0
of	of	IN	0
vitronectin	vitronectin	NN	B-NP
,	,	,	0
it	it	PRP	0
was	was	VBD	0
inhibited	inhibited	VBN	0
faster	faster	RBR	0
by	by	IN	0
mutant	mutant	NN	B-NP
than	than	IN	0
by	by	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
(	(	-LRB-	0
Fig.	Fig.	CD	0
6upper	6upper	CD	0
panel	panel	NN	0
)	)	-RRB-	0
;	;	:	0
and	and	CC	0
both	both	DT	0
of	of	IN	0
mutant	mutant	VBG	0
also	also	RB	0
displayed	displayed	VBN	0
improved	improved	JJ	0
inhibition	inhibition	NN	0
toward	toward	IN	0
plasmin	plasmin	NN	B-NP
in	in	IN	0
presence	presence	NN	0
of	of	IN	0
vitronectin	vitronectin	NN	B-NP
(	(	-LRB-	0
Fig.	Fig.	CD	0
6lower	6lower	CD	0
panel	panel	NN	0
)	)	-RRB-	0
.	.	.	0
Kinetic	Kinetic	JJ	B-NP
analysis	analysis	NN	I-NP
The	The	DT	0
rate	rate	NN	B-NP
constant	constant	JJ	I-NP
of	of	IN	0
tPA	tPA	JJ	0
for	for	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
Glu351Ala	Glu351Ala	NNP	0
and	and	CC	0
Glu351Arg	Glu351Arg	NNP	0
were	were	VBD	0
similar	similar	JJ	0
(	(	-LRB-	0
Table	Table	NNP	0
4	4	CD	0
)	)	-RRB-	0
,	,	,	0
however	however	RB	0
,	,	,	0
The	The	DT	0
rate	rate	NN	B-NP
constant	constant	JJ	I-NP
of	of	IN	0
inhibition	inhibition	NN	0
toward	toward	IN	0
uPA	uPA	JJ	0
by	by	IN	0
Glu351Ala	Glu351Ala	NNP	0
and	and	CC	0
Glu351Arg	Glu351Arg	NNP	0
were	were	VBD	0
4	4	CD	0
and	and	CC	0
7-fold	7-fold	CD	0
higher	higher	JJR	0
than	than	IN	0
by	by	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
respectively	respectively	RB	0
.	.	.	0
Moreover	Moreover	RB	0
,	,	,	0
The	The	DT	0
rate	rate	NN	B-NP
constant	constant	JJ	I-NP
of	of	IN	0
Glu351Ala	Glu351Ala	NNP	0
and	and	CC	0
Glu351Arg	Glu351Arg	CD	0
for	for	IN	0
thrombin	thrombin	JJ	B-NP
inhibition	inhibition	NN	I-NP
were	were	VBD	0
2	2	CD	0
to	to	TO	0
4	4	CD	0
folds	folds	CD	0
higher	higher	JJR	0
than	than	IN	0
that	that	DT	0
of	of	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
and	and	CC	0
rate	rate	NN	B-NP
constant	constant	JJ	I-NP
of	of	IN	0
Glu351Ala	Glu351Ala	NNP	0
and	and	CC	0
Glu351Arg	Glu351Arg	CD	0
to	to	TO	0
plasmin	plasmin	NN	B-NP
were	were	VBD	0
2	2	CD	0
fold	fold	CD	0
higher	higher	JJR	0
than	than	IN	0
that	that	DT	0
of	of	IN	0
wtPAI-1	wtPAI-1	CD	B-NP
.	.	.	0
This	This	DT	0
indicates	indicates	VBZ	0
that	that	IN	0
Glu351	Glu351	NNP	B-NP
is	is	VBZ	0
not	not	RB	0
essential	essential	JJ	0
for	for	IN	0
the	the	DT	0
interaction	interaction	NN	0
with	with	IN	0
type	type	NN	B-NP
plasminogen	plasminogen	NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
activator	activator	NN	I-NP
,	,	,	0
but	but	CC	0
it	it	PRP	0
is	is	VBZ	0
an	an	DT	0
very	very	RB	0
important	important	JJ	0
optimal	optimal	JJ	B-NP
interaction	interaction	NN	I-NP
determinant	determinant	NN	I-NP
with	with	IN	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
,	,	,	0
thrombin	thrombin	NN	B-NP
and	and	CC	0
plasmin	plasmin	NN	B-NP
.	.	.	0
Disscusion	Disscusion	FW	0
cognate	cognate	JJ	B-NP
protease	protease	NN	I-NP
specificity	specificity	NN	I-NP
improvement	improvement	NN	I-NP
in	in	IN	0
specificity	specificity	NN	0
of	of	IN	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
mutant	mutant	NN	I-NP
indicates	indicates	VBZ	0
that	that	IN	0
Glu351	Glu351	CD	B-NP
involve	involve	NN	0
in	in	IN	0
the	the	DT	0
interaction	interaction	NN	0
with	with	IN	0
uPA	uPA	JJ	0
.	.	.	0
To	To	TO	0
the	the	DT	0
best	best	JJS	0
of	of	IN	0
our	our	PRP$	0
knowledge	knowledge	NN	0
,	,	,	0
this	this	DT	0
is	is	VBZ	0
the	the	DT	0
first	first	JJ	0
time	time	NN	0
that	that	IN	0
the	the	DT	0
specificity	specificity	NN	0
of	of	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
toward	toward	IN	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
is	is	VBZ	0
partially	partially	RB	0
mediated	mediated	VBN	0
by	by	IN	0
the	the	DT	0
negatively	negatively	RB	0
charged	charged	VBN	0
residue	residue	RB	0
located	located	VBN	0
in	in	IN	0
the	the	DT	0
C-terminal	C-terminal	JJ	B-NP
of	of	IN	0
cleavage	cleavage	JJ	0
site	site	NN	0
in	in	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
.	.	.	0
The	The	DT	0
interaction	interaction	NN	0
of	of	IN	0
Glu351	Glu351	CD	B-NP
with	with	IN	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
is	is	VBZ	0
much	much	RB	0
more	more	RBR	0
important	important	JJ	0
than	than	IN	0
that	that	DT	0
of	of	IN	0
Glu351	Glu351	CD	B-NP
with	with	IN	0
type	type	NN	B-NP
plasminogen	plasminogen	NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
activator	activator	NN	I-NP
,	,	,	0
which	which	WDT	0
is	is	VBZ	0
demonstrated	demonstrated	VBN	0
by	by	IN	0
improved	improved	JJ	0
glu351	glu351	NN	B-NP
mutant	mutant	NN	I-NP
reactivity	reactivity	NN	I-NP
toward	toward	IN	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
,	,	,	0
but	but	CC	0
not	not	RB	0
toward	toward	IN	0
type	type	NN	B-NP
plasminogen	plasminogen	NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
activator	activator	NN	I-NP
,	,	,	0
showing	showing	VBG	0
that	that	IN	0
type	type	NN	B-NP
plasminogen	plasminogen	NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
activator	activator	NN	I-NP
is	is	VBZ	0
not	not	RB	0
directly	directly	RB	0
interact	interact	VBN	0
with	with	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
glu351	glu351	NN	I-NP
,	,	,	0
whereas	whereas	IN	0
Glu351	Glu351	NNP	B-NP
is	is	VBZ	0
necessary	necessary	JJ	0
for	for	IN	0
the	the	DT	0
optimal	optimal	JJ	B-NP
interaction	interaction	NN	I-NP
with	with	IN	0
uPA	uPA	JJ	0
.	.	.	0
Our	Our	PRP$	0
results	results	NNS	0
are	are	VBP	0
concordant	concordant	VBN	0
with	with	IN	0
previous	previous	JJ	0
study	study	NN	0
,	,	,	0
[	[	-LRB-	0
25	25	CD	0
]	]	-RRB-	0
which	which	WDT	0
suggests	suggests	VBZ	0
that	that	DT	0
serpin	serpin	JJ	B-NP
body-protease	body-protease	JJ	I-NP
body	body	NN	I-NP
interaction	interaction	NN	I-NP
play	play	VBP	0
significant	significant	JJ	0
roles	roles	NNS	0
in	in	IN	0
determining	determining	VBG	0
serpin	serpin	JJ	B-NP
inhibitory	inhibitory	JJ	I-NP
activity	activity	NN	I-NP
against	against	IN	0
target	target	NN	B-NP
protea	protea	NN	I-NP
.	.	.	0
glu351	glu351	NN	B-NP
non-cognate	non-cognate	NN	I-NP
protease	protease	JJ	I-NP
substitution	substitution	NN	I-NP
also	also	RB	0
altered	altered	VBN	0
the	the	DT	0
specificity	specificity	NN	0
toward	toward	IN	0
non-cognate	non-cognate	JJ	B-NP
protea	protea	NN	I-NP
:	:	:	0
plasmin	plasmin	NN	B-NP
and	and	CC	0
thrombin	thrombin	NN	B-NP
.	.	.	0
Glu	Glu	NNP	B-NP
at	at	IN	0
351	351	CD	0
may	may	MD	0
provide	provide	VB	0
steric	steric	JJ	B-NP
hindrance	hindrance	NN	I-NP
that	that	WDT	0
slows	slows	VBZ	0
the	the	DT	0
rate	rate	NN	0
of	of	IN	0
thrombin	thrombin	NN	B-NP
or	or	CC	0
plasmin	plasmin	JJ	B-NP
inhibition	inhibition	NN	I-NP
.	.	.	0
Mutations	Mutations	NNS	0
at	at	IN	0
Glu351	Glu351	NNP	B-NP
may	may	MD	0
decrease	decrease	VB	0
the	the	DT	0
original	original	JJ	B-NP
repulsive	repulsive	JJ	I-NP
interaction	interaction	NN	I-NP
with	with	IN	0
variable	variable	JJ	0
region	region	NN	0
of	of	IN	0
thrombin	thrombin	NN	B-NP
,	,	,	0
which	which	WDT	0
may	may	MD	0
slow	slow	VB	0
the	the	DT	0
rate	rate	NN	0
of	of	IN	0
thrombin	thrombin	JJ	B-NP
inhibition	inhibition	NN	I-NP
,	,	,	0
or	or	CC	0
results	results	NNS	0
in	in	IN	0
favorable	favorable	JJ	0
interaction	interaction	NN	B-NP
that	that	WDT	0
may	may	MD	0
not	not	RB	0
exist	exist	VB	0
when	when	WRB	0
wtPAI-1	wtPAI-1	RB	B-NP
react	react	VB	0
with	with	IN	0
thrombin	thrombin	NN	B-NP
.	.	.	0
So	So	RB	0
,	,	,	0
both	both	DT	0
Glu351Arg	Glu351Arg	NNP	0
and	and	CC	0
Glu351Arg	Glu351Arg	NNP	0
are	are	VBP	0
better	better	RBR	0
thrombin	thrombin	JJ	B-NP
inhibitor	inhibitor	NN	I-NP
than	than	IN	0
wtPAI-1	wtPAI-1	CD	B-NP
.	.	.	0
similar	similar	JJ	B-NP
result	result	NN	I-NP
were	were	VBD	0
observed	observed	VBN	0
for	for	IN	0
plasmin	plasmin	NN	B-NP
.	.	.	0
With	With	IN	0
single	single	JJ	0
mutation	mutation	NN	0
at	at	IN	0
position	position	NN	B-NP
Glu351	Glu351	NN	I-NP
,	,	,	0
we	we	PRP	0
improved	improved	VBD	0
reactivity	reactivity	VBN	0
of	of	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
to	to	TO	0
thrombin	thrombin	VB	0
and	and	CC	0
plasmin	plasmin	NN	B-NP
without	without	IN	0
significantly	significantly	RB	0
affecting	affecting	VBG	0
its	its	PRP$	0
specificity	specificity	NN	0
to	to	TO	0
tPA	tPA	JJ	0
.	.	.	0
This	This	DT	0
substantiates	substantiates	JJ	0
previous	previous	JJ	0
mutagenesis	mutagenesis	JJ	B-NP
study	study	NN	I-NP
,	,	,	0
which	which	WDT	0
demonstrated	demonstrated	VBD	0
that	that	DT	0
repulsive	repulsive	JJ	B-NP
interaction	interaction	NN	I-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
lack	lack	NN	0
of	of	IN	0
productive	productive	JJ	B-NP
electrostatic	electrostatic	JJ	I-NP
interaction	interaction	NN	I-NP
between	between	IN	0
Glu39	Glu39	NNP	B-NP
and	and	CC	0
thrombin	thrombin	NN	B-NP
glu192	glu192	NN	I-NP
and	and	CC	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
are	are	VBP	0
responsible	responsible	JJ	0
for	for	IN	0
the	the	DT	0
slow	slow	JJ	0
reaction	reaction	NN	0
of	of	IN	0
thrombin	thrombin	NN	B-NP
with	with	IN	0
this	this	DT	0
serpin.	serpin.	NNP	B-NP
[	[	-LRB-	0
26	26	CD	0
]	]	-RRB-	0
Furthermore	Furthermore	RB	0
,	,	,	0
the	the	DT	0
plasmin	plasmin	NN	B-NP
rapid	rapid	JJ	I-NP
inhibition	inhibition	NN	I-NP
requires	requires	VBZ	0
a	a	DT	0
non-covalent	non-covalent	JJ	B-NP
interaction	interaction	NN	I-NP
between	between	IN	0
an	an	DT	0
plasmin	plasmin	NN	B-NP
amino-terminal	amino-terminal	JJ	I-NP
site	site	NN	I-NP
and	and	CC	0
a	a	DT	0
carboxyl-terminal	carboxyl-terminal	JJ	B-NP
on	on	IN	0
anti-plasmin	anti-plasmin	NNP	B-NP
,	,	,	0
and	and	CC	0
a	a	DT	0
second	second	JJ	0
site	site	NN	0
outside	outside	IN	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
rcl	rcl	NN	I-NP
contributes	contributes	VBZ	0
to	to	TO	0
its	its	PRP$	0
specific	specific	JJ	0
interaction	interaction	NN	0
with	with	IN	0
protea	protea	NN	B-NP
[	[	-LRB-	0
15	15	CD	0
27	27	CD	0
]	]	-RRB-	0
The	The	DT	0
specificity	specificity	NN	0
of	of	IN	0
the	the	DT	0
two	two	CD	0
mutant	mutant	NN	B-NP
toward	toward	IN	0
thrombin	thrombin	NN	B-NP
and	and	CC	0
plasmin	plasmin	JJ	0
implicates	implicates	NN	0
that	that	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
glu351	glu351	NN	I-NP
is	is	VBZ	0
involved	involved	VBN	0
in	in	IN	0
its	its	PRP$	0
specificity	specificity	NN	0
toward	toward	IN	0
thrombin	thrombin	NN	B-NP
and	and	CC	0
plasmin	plasmin	NN	B-NP
.	.	.	0
conclusion	conclusion	NN	B-NP
single	single	JJ	I-NP
site	site	NN	I-NP
mutation	mutation	NN	I-NP
within	within	IN	0
the	the	DT	0
activatable	activatable	JJ	B-NP
inhibitor	inhibitor	NN	I-NP
pai-1	pai-1	NN	I-NP
yield	yield	NN	I-NP
gdn-hcl	gdn-hcl	NN	I-NP
segment	segment	NN	I-NP
asp355-arg356-pro357	asp355-arg356-pro357	NN	I-NP
that	that	WDT	0
can	can	MD	0
still	still	RB	0
form	form	VB	0
sd	sd	NN	B-NP
stable	stable	JJ	I-NP
complex	complex	JJ	I-NP
with	with	IN	0
plasminogen	plasminogen	JJ	B-NP
activator	activator	NN	I-NP
,	,	,	0
with	with	IN	0
second	second	JJ	0
order	order	NN	B-NP
inhibition	inhibition	NN	I-NP
constant	constant	JJ	I-NP
that	that	WDT	0
are	are	VBP	0
similar	similar	JJ	0
to	to	TO	0
the	the	DT	0
native	native	JJ	0
inhibitor	inhibitor	NN	0
.	.	.	0
Interestingly	Interestingly	RB	0
,	,	,	0
the	the	DT	0
conversion	conversion	NN	0
of	of	IN	0
these	these	DT	0
mutant	mutant	NN	B-NP
to	to	TO	0
latent	latent	VB	0
forms	forms	NNS	0
was	was	VBD	0
~3-4	~3-4	RB	0
fold	fold	VB	0
faster	faster	RBR	0
than	than	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
suggesting	suggesting	VBG	0
that	that	IN	0
the	the	DT	0
Asp355-Pro357	Asp355-Pro357	JJ	B-NP
segment	segment	NN	I-NP
is	is	VBZ	0
involved	involved	VBN	0
in	in	IN	0
maintaining	maintaining	VBG	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
inhibitory	inhibitory	JJ	I-NP
conformation	conformation	NN	I-NP
.	.	.	0
Glu351	Glu351	NNP	B-NP
contributes	contributes	VBZ	0
to	to	TO	0
the	the	DT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
optimal	optimal	JJ	I-NP
functional	functional	JJ	I-NP
stability	stability	NN	I-NP
and	and	CC	0
participates	participates	VBZ	0
its	its	PRP$	0
conformational	conformational	JJ	B-NP
stability	stability	NN	I-NP
.	.	.	0
More	More	RBR	0
importantly	importantly	RB	0
,	,	,	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
glu351	glu351	NN	I-NP
is	is	VBZ	0
a	a	DT	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
specificity	specificity	JJ	I-NP
determinant	determinant	NN	I-NP
,	,	,	0
thrombin	thrombin	NN	B-NP
and	and	CC	0
plasmin	plasmin	NN	B-NP
,	,	,	0
but	but	CC	0
not	not	RB	0
for	for	IN	0
tPA	tPA	JJ	0
.	.	.	0
Methods	Methods	NNP	0
plasmid	plasmid	NN	B-NP
dna	dna	NN	I-NP
general	general	JJ	I-NP
dna	dna	NN	I-NP
technique	technique	NN	I-NP
was	was	VBD	0
purified	purified	VBN	0
using	using	VBG	0
either	either	DT	0
Promega	Promega	NNP	B-NP
or	or	CC	0
qiagen	qiagen	NN	B-NP
miniprep	miniprep	NN	I-NP
kit	kit	NN	I-NP
.	.	.	0
The	The	DT	0
DNA	DNA	NN	B-NP
was	was	VBD	0
sequenced	sequenced	VBN	0
using	using	VBG	0
the	the	DT	0
di-deoxy	di-deoxy	JJ	B-NP
chain	chain	NN	I-NP
termination	termination	NN	I-NP
reaction	reaction	NN	I-NP
method	method	NN	I-NP
using	using	VBG	0
an	an	DT	0
ABI	ABI	NNP	B-NP
373	373	CD	0
DNA	DNA	NN	B-NP
sequencer	sequencer	NN	I-NP
.	.	.	0
oligonucleotide	oligonucleotide	NN	B-NP
were	were	VBD	0
synthesized	synthesized	VBN	0
using	using	VBG	0
a	a	DT	0
380	380	CD	0
B	B	NNP	B-NP
DNA	DNA	NNP	I-NP
synthesizer	synthesizer	NN	I-NP
(	(	-LRB-	0
ABI	ABI	NNP	B-NP
model	model	NN	I-NP
)	)	-RRB-	0
.	.	.	0
dna	dna	NN	B-NP
manipulation	manipulation	NN	I-NP
technique	technique	NN	I-NP
were	were	VBD	0
carried	carried	VBN	0
out	out	RP	0
according	according	VBG	0
to	to	TO	0
standard	standard	JJ	0
procedures	procedures	NNS	0
[	[	-LRB-	0
29	29	CD	0
]	]	-RRB-	0
.	.	.	0
wtpai-1	wtpai-1	NN	B-NP
construction	construction	NN	I-NP
and	and	CC	0
its	its	PRP$	0
mutant	mutant	NN	B-NP
The	The	DT	0
pPAI-1-AI	pPAI-1-AI	NNP	B-NP
was	was	VBD	0
digested	digested	VBN	0
with	with	IN	0
EcoRI	EcoRI	JJ	0
and	and	CC	0
BglII	BglII	JJ	0
to	to	TO	0
release	release	VB	0
a	a	DT	0
1426	1426	CD	0
basepair	basepair	NN	B-NP
(	(	-LRB-	0
bp	bp	LS	B-NP
)	)	-RRB-	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
coding	coding	FW	0
sequence	sequence	FW	0
,	,	,	0
which	which	WDT	0
was	was	VBD	0
isolated	isolated	VBN	0
,	,	,	0
purified	purified	NN	0
,	,	,	0
and	and	CC	0
ligated	ligated	NN	0
into	into	IN	0
EcoRI	EcoRI	JJ	0
and	and	CC	0
BglII	BglII	JJ	B-NP
digested	digested	JJ	I-NP
pVL1393	pVL1393	NN	0
.	.	.	0
The	The	DT	0
resultant	resultant	JJ	0
pVL1393-PAI-1	pVL1393-PAI-1	NN	B-NP
was	was	VBD	0
analyzed	analyzed	VBN	0
by	by	IN	0
restriction	restriction	NN	B-NP
mapping	mapping	NN	I-NP
and	and	CC	0
sequencing	sequencing	NN	B-NP
.	.	.	0
The	The	DT	0
mutant	mutant	NN	B-NP
at	at	IN	0
E351A	E351A	NNP	0
,	,	,	0
E351R	E351R	NNP	0
,	,	,	0
D355	D355	NNP	B-NP
,	,	,	0
R356	R356	NNP	B-NP
,	,	,	0
and	and	CC	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
p357	p357	NN	I-NP
were	were	VBD	0
generated	generated	VBN	0
by	by	IN	0
PCR	PCR	NNP	B-NP
.	.	.	0
The	The	DT	0
occurrence	occurrence	NN	0
of	of	IN	0
the	the	DT	0
resulting	resulting	VBG	B-NP
mutation	mutation	NN	I-NP
D355A	D355A	NN	0
,	,	,	0
D355E	D355E	NNP	0
,	,	,	0
D355H	D355H	NNP	0
,	,	,	0
D355K	D355K	NNP	0
,	,	,	0
D355N	D355N	NNP	0
,	,	,	0
D355P	D355P	NNP	0
,	,	,	0
D355Q	D355Q	NNP	0
,	,	,	0
R356P	R356P	NNP	0
,	,	,	0
P357G	P357G	NNP	0
as	as	IN	0
well	well	RB	0
as	as	IN	0
E351A	E351A	NNP	0
and	and	CC	0
E351R	E351R	CD	0
in	in	IN	0
pRSET	pRSET	NNP	B-NP
was	was	VBD	0
confirmed	confirmed	VBN	0
by	by	IN	0
sequencing	sequencing	NN	B-NP
.	.	.	0
The	The	DT	0
PAI-1	PAI-1	JJ	B-NP
sequence	sequence	NN	I-NP
containing	containing	VBG	0
the	the	DT	0
desired	desired	JJ	0
mutations	mutations	NNS	0
was	was	VBD	0
digested	digested	VBN	0
with	with	IN	0
EcoR1	EcoR1	NNP	B-NP
and	and	CC	0
BglII	BglII	JJ	0
,	,	,	0
and	and	CC	0
then	then	RB	0
subcloned	subcloned	VBN	0
into	into	IN	0
pVL1393	pVL1393	CD	0
.	.	.	0
The	The	DT	0
recombinant	recombinant	JJ	0
baculoviru	baculoviru	NN	B-NP
containing	containing	VBG	0
either	either	DT	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
or	or	CC	0
one	one	CD	0
of	of	IN	0
the	the	DT	0
above	above	JJ	0
mutant	mutant	NN	B-NP
was	was	VBD	0
obtained	obtained	VBN	0
as	as	IN	0
deccribed	deccribed	NN	0
by	by	IN	0
Kjoller	Kjoller	NNP	B-NP
et	et	FW	0
al.	al.	FW	0
[	[	-LRB-	0
30	30	CD	0
]	]	-RRB-	0
Expression	Expression	NNP	0
and	and	CC	0
wtpai-1	wtpai-1	NN	B-NP
purification	purification	NN	I-NP
and	and	CC	0
its	its	PRP$	0
mutants	mutants	JJ	0
High	High	NNP	0
5	5	CD	0
cells	cells	NNS	0
,	,	,	0
grown	grown	VBN	0
at	at	IN	0
27°C	27°C	CD	0
in	in	IN	0
SF-900	SF-900	CD	B-NP
serum-free	serum-free	JJ	I-NP
medium	medium	NN	I-NP
,	,	,	0
were	were	VBD	0
infected	infected	VBN	0
with	with	IN	0
high-titer	high-titer	JJ	B-NP
virus	virus	NN	I-NP
stock	stock	NN	I-NP
(	(	-LRB-	0
1-3	1-3	CD	0
×	×	CD	0
10	10	CD	0
8	8	CD	0
/	/	CD	0
ml	ml	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
medium	medium	NN	0
was	was	VBD	0
collected	collected	VBN	0
48	48	CD	0
hr	hr	NN	B-NP
after	after	IN	0
the	the	DT	0
infection	infection	NN	B-NP
(	(	-LRB-	0
found	found	VBN	0
to	to	TO	0
be	be	VB	0
the	the	DT	0
wtpai-1	wtpai-1	NN	B-NP
optimal	optimal	JJ	I-NP
harvesting	harvesting	JJ	I-NP
time	time	NN	I-NP
)	)	-RRB-	0
and	and	CC	0
then	then	RB	0
centrifuged	centrifuged	VBN	0
for	for	IN	0
5	5	CD	0
minutes	minutes	NNS	0
(	(	-LRB-	0
125	125	CD	0
×	×	CD	0
g	g	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
supernatent	supernatent	NN	B-NP
(	(	-LRB-	0
50	50	CD	0
ml	ml	CD	0
)	)	-RRB-	0
were	were	VBD	0
collected	collected	VBN	0
and	and	CC	0
sodium	sodium	JJ	B-NP
chloride	chloride	NN	I-NP
(	(	-LRB-	0
final	final	JJ	B-NP
concentration	concentration	NN	I-NP
0.25	0.25	CD	0
M	M	NNP	0
)	)	-RRB-	0
was	was	VBD	0
added	added	VBN	0
.	.	.	0
They	They	PRP	0
were	were	VBD	0
then	then	RB	0
applied	applied	VBN	0
on	on	IN	0
a	a	DT	0
heparin-Sepharose	heparin-Sepharose	JJ	B-NP
column	column	NN	I-NP
(	(	-LRB-	0
bed	bed	NN	0
volume	volume	NN	0
5	5	CD	0
ml	ml	CD	0
)	)	-RRB-	0
that	that	WDT	0
was	was	VBD	0
equilibrated	equilibrated	JJ	0
and	and	CC	0
run	run	VB	0
(	(	-LRB-	0
flow	flow	NN	B-NP
rate	rate	NN	I-NP
20	20	CD	0
ml	ml	CD	B-NP
/	/	CD	I-NP
h	h	CD	I-NP
)	)	-RRB-	0
with	with	IN	0
a	a	DT	0
buffer	buffer	NN	B-NP
consisted	consisted	VBD	0
of	of	IN	0
50	50	CD	0
mM	mM	JJ	B-NP
sodium	sodium	JJ	I-NP
acetate	acetate	NN	I-NP
,	,	,	0
pH	pH	JJ	0
5.6	5.6	CD	0
,	,	,	0
containing	containing	VBG	0
0.25	0.25	CD	0
M	M	NNP	0
NaCl	NaCl	NNP	B-NP
and	and	CC	0
0.01	0.01	CD	0
%	%	NN	0
Tween-20	Tween-20	NN	B-NP
.	.	.	0
The	The	DT	0
columns	columns	NNS	0
were	were	VBD	0
washed	washed	VBN	0
and	and	CC	0
the	the	DT	0
PAI-1s	PAI-1s	NNP	B-NP
were	were	VBD	0
eluted	eluted	VBN	0
with	with	IN	0
a	a	DT	0
40	40	CD	0
ml	ml	JJ	B-NP
gradient	gradient	NN	I-NP
of	of	IN	0
0.25	0.25	CD	0
-	-	:	0
1	1	CD	0
M	M	NNP	0
NaCl	NaCl	NNP	B-NP
in	in	IN	0
the	the	DT	0
same	same	JJ	0
buffer	buffer	NN	B-NP
.	.	.	0
SDS-PAGE	SDS-PAGE	NNP	B-NP
,	,	,	0
immunoblotting	immunoblotting	NN	B-NP
and	and	CC	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
deglycosylation	deglycosylation	NN	I-NP
The	The	DT	0
medium	medium	NN	0
of	of	IN	0
the	the	DT	0
infected	infected	JJ	0
cells	cells	NNS	0
and	and	CC	0
the	the	DT	0
elutent	elutent	NN	B-NP
from	from	IN	0
heparin-Sepharose	heparin-Sepharose	NNP	B-NP
were	were	VBD	0
separated	separated	VBN	0
on	on	IN	0
10	10	CD	0
%	%	NN	0
SDS-PAGE	SDS-PAGE	NN	B-NP
,	,	,	0
and	and	CC	0
monitored	monitored	VBN	0
by	by	IN	0
silver	silver	JJ	0
staining	staining	NN	0
.	.	.	0
Fibrosarcoma	Fibrosarcoma	NNP	B-NP
PAI-1	PAI-1	NNP	I-NP
and	and	CC	0
wtPAI-1	wtPAI-1	NNP	B-NP
were	were	VBD	0
transferred	transferred	VBN	0
onto	onto	IN	0
nitrocellulose	nitrocellulose	JJ	B-NP
paper	paper	NN	I-NP
and	and	CC	0
the	the	DT	0
proteins	proteins	NNS	0
were	were	VBD	0
revealed	revealed	VBN	0
with	with	IN	0
monoclonal	monoclonal	CD	B-NP
antibody	antibody	NN	I-NP
anti-human	anti-human	JJ	I-NP
pai-1	pai-1	NN	I-NP
,	,	,	0
followed	followed	VBN	0
by	by	IN	0
horseradish	horseradish	JJ	B-NP
peroxidasa	peroxidasa	NN	I-NP
(	(	-LRB-	0
horseradish	horseradish	NN	B-NP
peroxidase	peroxidase	NN	I-NP
)	)	-RRB-	0
conjugated	conjugated	JJ	0
rabbit	rabbit	JJ	B-NP
anti-mouse	anti-mouse	JJ	I-NP
antibody	antibody	NN	I-NP
,	,	,	0
and	and	CC	0
enhanced	enhanced	JJ	B-NP
chemiluminescenca	chemiluminescenca	NN	I-NP
(	(	-LRB-	0
ECL	ECL	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
5	5	CD	0
fibrosarcoma	fibrosarcoma	NN	B-NP
pai-1	pai-1	NN	I-NP
ug	ug	NN	I-NP
,	,	,	0
or	or	CC	0
wtPAI-1	wtPAI-1	NNP	B-NP
was	was	VBD	0
denatured	denatured	VBN	0
by	by	IN	0
boiling	boiling	VBG	0
for	for	IN	0
5	5	CD	0
min	min	NN	B-NP
in	in	IN	0
a	a	DT	0
buffer	buffer	NN	B-NP
consisted	consisted	VBD	0
of	of	IN	0
0.5	0.5	CD	0
%	%	NN	0
sd	sd	NN	B-NP
,	,	,	0
50	50	CD	0
mM	mM	JJ	B-NP
β-mercaptoethanol	β-mercaptoethanol	JJ	I-NP
and	and	CC	0
50	50	CD	0
mM	mM	JJ	B-NP
Tris-HCl	Tris-HCl	NN	I-NP
,	,	,	0
pH	pH	JJ	0
7.4	7.4	CD	0
.	.	.	0
They	They	PRP	0
were	were	VBD	0
then	then	RB	0
digested	digested	VBN	0
(	(	-LRB-	0
18	18	CD	0
hr	hr	NN	B-NP
,	,	,	0
at	at	IN	0
37°C	37°C	CD	0
)	)	-RRB-	0
with	with	IN	0
0.5	0.5	CD	0
units	units	NNS	0
of	of	IN	0
recombinant	recombinant	JJ	0
N-glycanase	N-glycanase	NN	B-NP
in	in	IN	0
the	the	DT	0
presence	presence	NN	0
of	of	IN	0
2.5	2.5	CD	0
%	%	NN	0
NP-40	NP-40	NN	B-NP
,	,	,	0
and	and	CC	0
subjected	subjected	VBN	0
to	to	TO	0
SDS-PAGE	SDS-PAGE	JJ	B-NP
and	and	CC	0
silver	silver	JJ	0
staining	staining	NN	0
.	.	.	0
protein	protein	NN	B-NP
concentration	concentration	NN	I-NP
were	were	VBD	0
determined	determined	VBN	0
by	by	IN	0
the	the	DT	0
Bio-Rad	Bio-Rad	JJ	B-NP
protein	protein	NN	I-NP
assay	assay	NN	I-NP
reagent	reagent	NN	I-NP
.	.	.	0
fibrosarcoma	fibrosarcoma	CD	B-NP
pai-1	pai-1	NN	I-NP
functional	functional	JJ	I-NP
stability	stability	NN	I-NP
,	,	,	0
wtPAI-1	wtPAI-1	NNP	B-NP
and	and	CC	0
its	its	PRP$	0
mutant	mutant	NN	B-NP
The	The	DT	0
fibrosarcoma	fibrosarcoma	CD	B-NP
pai-1	pai-1	NN	I-NP
inhibitory	inhibitory	JJ	I-NP
activity	activity	NN	I-NP
,	,	,	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
and	and	CC	0
its	its	PRP$	0
mutant	mutant	NN	B-NP
were	were	VBD	0
measured	measured	VBN	0
by	by	IN	0
a	a	DT	0
direct	direct	JJ	0
chromogenic	chromogenic	NN	B-NP
assay	assay	VBP	0
using	using	VBG	0
uPA	uPA	JJ	0
(	(	-LRB-	0
100	100	CD	0
U	U	NNP	B-NP
/	/	CD	I-NP
ug	ug	CD	I-NP
)	)	-RRB-	0
and	and	CC	0
its	its	PRP$	0
substrate	substrate	JJ	B-NP
S-2444	S-2444	NN	I-NP
in	in	IN	0
a	a	DT	0
microtiter	microtiter	JJ	B-NP
plate	plate	NN	I-NP
as	as	IN	0
described	described	VBN	0
earlier	earlier	RBR	0
[	[	-LRB-	0
20	20	CD	0
]	]	-RRB-	0
.	.	.	0
Briefly	Briefly	RB	0
,	,	,	0
fibrosarcoma	fibrosarcoma	CD	B-NP
PAI-1	PAI-1	CD	I-NP
,	,	,	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
or	or	CC	0
its	its	PRP$	0
mutant	mutant	NN	B-NP
were	were	VBD	0
diluted	diluted	VBN	0
1	1	CD	0
:	:	:	0
10	10	CD	0
in	in	IN	0
the	the	DT	0
activity	activity	NN	0
measuring	measuring	VBG	B-NP
assay	assay	JJ	I-NP
buffer	buffer	NN	I-NP
(	(	-LRB-	0
50	50	CD	0
uM	uM	JJ	B-NP
Tris-HCl	Tris-HCl	NN	I-NP
,	,	,	0
pH	pH	JJ	0
7.5	7.5	CD	0
,	,	,	0
containing	containing	VBG	0
0.15	0.15	NNP	0
M	M	NNP	0
NaCl	NaCl	NNP	B-NP
and	and	CC	0
100	100	CD	0
ug	ug	NN	B-NP
/	/	NN	I-NP
ml	ml	NN	I-NP
BSA	BSA	NN	I-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
pai-1	pai-1	NN	B-NP
sample	sample	NN	I-NP
were	were	VBD	0
incubated	incubated	VBN	0
in	in	IN	0
the	the	DT	0
absence	absence	NN	B-NP
or	or	CC	0
in	in	IN	0
the	the	DT	0
presence	presence	NN	0
of	of	IN	0
a	a	DT	0
two	two	CD	0
vitronectin	vitronectin	NNS	B-NP
molar	molar	JJ	I-NP
excess	excess	NN	I-NP
(	(	-LRB-	0
the	the	DT	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
PAI-1	PAI-1	NN	I-NP
and	and	CC	0
the	the	DT	0
wtPAI-1	wtPAI-1	NNP	B-NP
were	were	VBD	0
incubated	incubated	VBN	0
with	with	IN	0
vitronectin	vitronectin	CD	B-NP
)	)	-RRB-	0
at	at	IN	0
37°C	37°C	CD	0
.	.	.	0
At	At	IN	0
the	the	DT	0
times	times	NNS	0
indicated	indicated	VBD	0
,	,	,	0
aliquot	aliquot	NN	B-NP
were	were	VBD	0
removed	removed	VBN	0
and	and	CC	0
analyzed	analyzed	VBD	0
immediately	immediately	RB	0
for	for	IN	0
their	their	PRP$	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
.	.	.	0
One	One	CD	0
unit	unit	NN	0
of	of	IN	0
PAI-1	PAI-1	CD	B-NP
activity	activity	NN	I-NP
is	is	VBZ	0
defined	defined	VBN	0
as	as	IN	0
the	the	DT	0
amount	amount	NN	0
that	that	WDT	0
completely	completely	RB	0
neutralizes	neutralizes	CD	0
1	1	CD	0
U	U	NNP	0
of	of	IN	0
uPA	uPA	JJ	0
.	.	.	0
The	The	DT	0
specific	specific	JJ	0
activity	activity	NN	0
obtained	obtained	VBN	0
at	at	IN	0
time	time	NN	0
zero	zero	NN	0
was	was	VBD	0
assigned	assigned	VBN	0
a	a	DT	0
value	value	NN	0
of	of	IN	0
100	100	CD	0
%	%	NN	0
.	.	.	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
activation	activation	NN	I-NP
and	and	CC	0
kinetic	kinetic	JJ	B-NP
analysis	analysis	NN	I-NP
Fibrosarcoma	Fibrosarcoma	NNP	I-NP
PAI-1	PAI-1	NNP	I-NP
,	,	,	0
wtPAI-1	wtPAI-1	NNP	B-NP
or	or	CC	0
its	its	PRP$	0
mutant	mutant	NN	B-NP
were	were	VBD	0
denatured	denatured	VBN	0
with	with	IN	0
6	6	CD	0
M	M	NNP	0
guanidine-hydrochloride	guanidine-hydrochloride	NNP	B-NP
(	(	-LRB-	0
Gdn-HCl	Gdn-HCl	NNP	B-NP
)	)	-RRB-	0
(	(	-LRB-	0
45	45	CD	0
min	min	NN	B-NP
at	at	IN	0
37°C	37°C	CD	0
)	)	-RRB-	0
,	,	,	0
followed	followed	VBN	0
by	by	IN	0
dialysis	dialysis	NN	0
(	(	-LRB-	0
4-16	4-16	CD	0
hours	hours	NNS	0
at	at	IN	0
4°C	4°C	CD	0
)	)	-RRB-	0
against	against	IN	0
50	50	CD	0
mM	mM	JJ	B-NP
sodium	sodium	JJ	I-NP
acetate	acetate	NN	I-NP
,	,	,	0
pH	pH	JJ	0
5.6	5.6	CD	0
,	,	,	0
containing	containing	VBG	0
0.5	0.5	CD	0
M	M	NNP	0
NaCl	NaCl	NNP	B-NP
and	and	CC	0
0.01	0.01	CD	0
%	%	NN	0
Tween-20	Tween-20	NN	B-NP
.	.	.	0
This	This	DT	0
process	process	NN	0
which	which	WDT	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
regained	regained	VBN	0
its	its	PRP$	0
activity	activity	NN	0
is	is	VBZ	0
called	called	VBN	B-NP
activation	activation	VBN	I-NP
by	by	IN	0
guanidine	guanidine	NN	B-NP
hydrochloride	hydrochloride	NN	I-NP
.	.	.	0
The	The	DT	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
of	of	IN	0
each	each	DT	0
of	of	IN	0
the	the	DT	0
PAI-1s	PAI-1s	NNP	B-NP
was	was	VBD	0
assayed	assayed	VBN	0
immediately	immediately	RB	0
.	.	.	0
The	The	DT	0
second-order	second-order	JJ	B-NP
rate	rate	NN	I-NP
constant	constant	JJ	I-NP
for	for	IN	0
the	the	DT	0
interaction	interaction	NN	0
of	of	IN	0
the	the	DT	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
PAI-1	PAI-1	NN	I-NP
,	,	,	0
wtPAI-1	wtPAI-1	NNP	B-NP
or	or	CC	0
the	the	DT	0
indicated	indicated	JJ	0
mutant	mutant	NN	B-NP
with	with	IN	0
single-chain	single-chain	JJ	B-NP
tPA	tPA	JJ	0
or	or	CC	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
were	were	VBD	0
determined	determined	VBN	0
in	in	IN	0
a	a	DT	0
single-step	single-step	JJ	B-NP
assay	assay	NN	I-NP
as	as	IN	0
previously	previously	RB	0
described.	described.	CD	0
[	[	-LRB-	0
20	20	CD	0
]	]	-RRB-	0
Specific	Specific	JJ	0
activity	activity	NN	0
,	,	,	0
functional	functional	JJ	B-NP
stability	stability	NN	I-NP
and	and	CC	0
complex	complex	JJ	0
formation	formation	NN	0
of	of	IN	0
PAI-1s	PAI-1s	CD	B-NP
The	The	DT	0
wtpai-1	wtpai-1	NN	B-NP
inhibitory	inhibitory	JJ	I-NP
activity	activity	NN	I-NP
and	and	CC	0
mutant	mutant	NN	B-NP
were	were	VBD	0
measured	measured	VBN	0
by	by	IN	0
a	a	DT	0
direct	direct	JJ	0
chromogenic	chromogenic	NN	B-NP
assay	assay	VBP	0
using	using	VBG	0
uPA	uPA	JJ	0
(	(	-LRB-	0
100	100	CD	0
U	U	NNP	B-NP
/	/	CD	I-NP
μg	μg	CD	I-NP
)	)	-RRB-	0
and	and	CC	0
substrate	substrate	CD	B-NP
S-2444.	S-2444.	CD	I-NP
[	[	-LRB-	0
17	17	CD	0
]	]	-RRB-	0
Briefly	Briefly	NNP	0
,	,	,	0
serially	serially	VBD	0
diluted	diluted	VBN	B-NP
wtPAI-1	wtPAI-1	NNP	I-NP
,	,	,	0
or	or	CC	0
mutant	mutant	NN	B-NP
were	were	VBD	0
incubated	incubated	VBN	0
with	with	IN	0
equal	equal	JJ	0
volume	volume	NN	0
of	of	IN	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
(	(	-LRB-	0
50	50	CD	0
μl	μl	NN	B-NP
,	,	,	0
50	50	CD	0
U	U	NNP	B-NP
/	/	CD	I-NP
ml	ml	CD	I-NP
)	)	-RRB-	0
for	for	IN	0
30	30	CD	0
min	min	NN	B-NP
at	at	IN	0
37°C	37°C	NNP	0
,	,	,	0
followed	followed	VBN	0
by	by	IN	0
addition	addition	NN	B-NP
of	of	IN	0
100	100	CD	0
μl	μl	NN	B-NP
,	,	,	0
0.5	0.5	CD	0
mM	mM	JJ	B-NP
S-2444	S-2444	NN	I-NP
.	.	.	0
Residual	Residual	JJ	B-NP
uPA	uPA	JJ	I-NP
activity	activity	NN	I-NP
was	was	VBD	0
quantitated	quantitated	VBN	0
by	by	IN	0
measuring	measuring	VBG	0
the	the	DT	0
change	change	NN	0
in	in	IN	0
absorbance	absorbance	NN	B-NP
at	at	IN	0
405	405	CD	0
nm	nm	NN	B-NP
with	with	IN	0
ELISA	ELISA	NNP	B-NP
reader	reader	NN	I-NP
.	.	.	0
The	The	DT	0
specific	specific	JJ	0
activity	activity	NN	0
of	of	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
was	was	VBD	0
calculated	calculated	VBN	0
based	based	VBN	0
on	on	IN	0
the	the	DT	0
amount	amount	NN	0
of	of	IN	0
uPA	uPA	JJ	B-NP
inhibited	inhibited	NN	I-NP
by	by	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
.	.	.	0
The	The	DT	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
assay	assay	NN	I-NP
toward	toward	IN	0
two-chain	two-chain	JJ	B-NP
tPA	tPA	NN	I-NP
was	was	VBD	0
the	the	DT	0
same	same	JJ	0
for	for	IN	0
uPA	uPA	JJ	0
except	except	NN	0
that	that	IN	0
the	the	DT	0
samples	samples	NNS	0
were	were	VBD	0
incubated	incubated	VBN	0
with	with	IN	0
tPA	tPA	JJ	0
and	and	CC	0
S-2288	S-2288	NNP	B-NP
.	.	.	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
is	is	VBZ	0
expressed	expressed	VBN	0
as	as	IN	0
the	the	DT	0
number	number	NN	0
of	of	IN	0
international	international	JJ	0
units	units	NNS	0
of	of	IN	0
PAs	PAs	JJ	B-NP
inhibited	inhibited	NN	0
by	by	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
.	.	.	0
Specific	Specific	JJ	0
activity	activity	NN	0
of	of	IN	0
uPA	uPA	JJ	0
and	and	CC	0
two-chain	two-chain	JJ	B-NP
tPA	tPA	NN	I-NP
are	are	VBP	0
100	100	CD	0
U	U	NNP	B-NP
/	/	NNP	I-NP
μg	μg	NN	I-NP
and	and	CC	0
764	764	CD	0
U	U	NNP	B-NP
/	/	NNP	I-NP
μg	μg	NN	I-NP
,	,	,	0
respectively	respectively	RB	0
.	.	.	0
For	For	IN	0
the	the	DT	0
functional	functional	JJ	B-NP
stability	stability	NN	I-NP
,	,	,	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
or	or	CC	0
mutant	mutant	NN	B-NP
were	were	VBD	0
incubated	incubated	VBN	0
at	at	IN	0
37°C	37°C	CD	0
.	.	.	0
aliquot	aliquot	NN	B-NP
were	were	VBD	0
taken	taken	VBN	0
out	out	RP	0
at	at	IN	0
times	times	NNS	0
indicated	indicated	VBD	0
and	and	CC	0
analyzed	analyzed	VBD	0
immediately	immediately	RB	0
as	as	RB	0
described	described	VBN	0
above	above	IN	0
.	.	.	0
The	The	DT	0
specific	specific	JJ	0
activity	activity	NN	0
obtained	obtained	VBN	0
at	at	IN	0
time	time	NN	0
zero	zero	NN	0
was	was	VBD	0
assigned	assigned	VBN	0
a	a	DT	0
value	value	NN	0
of	of	IN	0
100	100	CD	0
%	%	NN	0
.	.	.	0
To	To	TO	0
provide	provide	VB	0
the	the	DT	0
evidence	evidence	NN	0
to	to	TO	0
support	support	VB	0
the	the	DT	0
conclusion	conclusion	NN	0
obtained	obtained	VBN	0
from	from	IN	0
enzyme	enzyme	JJ	B-NP
assay	assay	NN	I-NP
,	,	,	0
certain	certain	JJ	0
amount	amount	NN	0
of	of	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
E351R	E351R	NNP	0
and	and	CC	0
E351A	E351A	NNP	0
were	were	VBD	0
incubated	incubated	VBN	0
with	with	IN	0
equal	equal	JJ	0
amount	amount	NN	0
of	of	IN	0
tPA	tPA	JJ	0
at	at	IN	0
37°C	37°C	CD	0
for	for	IN	0
30	30	CD	0
minutes	minutes	NNS	0
before	before	IN	0
put	put	VBN	0
on	on	IN	0
ice	ice	NN	0
,	,	,	0
at	at	IN	0
same	same	JJ	0
time	time	NN	0
these	these	DT	0
PAI-1s	PAI-1s	NNP	B-NP
were	were	VBD	0
incubated	incubated	VBN	0
in	in	IN	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
at	at	IN	0
37°C	37°C	CD	0
for	for	IN	0
3	3	CD	0
hours	hours	NNS	0
,	,	,	0
respectively	respectively	RB	0
,	,	,	0
before	before	IN	0
the	the	DT	0
PAI-1s	PAI-1s	NNP	B-NP
were	were	VBD	0
incubated	incubated	VBN	0
with	with	IN	0
same	same	JJ	0
amount	amount	NN	0
of	of	IN	0
tPA	tPA	JJ	0
at	at	IN	0
37°C	37°C	CD	0
for	for	IN	0
30	30	CD	0
minutes	minutes	NNS	0
,	,	,	0
then	then	RB	0
the	the	DT	0
protein	protein	NN	0
samples	samples	NNS	0
prepared	prepared	VBN	0
at	at	IN	0
two	two	CD	0
time	time	NN	B-NP
point	point	NN	I-NP
were	were	VBD	0
subjected	subjected	VBN	0
to	to	TO	0
SDS-PAGE	SDS-PAGE	JJ	B-NP
and	and	CC	0
western	western	JJ	0
blot	blot	NN	0
as	as	IN	0
described	described	VBN	0
before	before	RB	0
.	.	.	0
Inhibition	Inhibition	NNP	0
of	of	IN	0
thrombin	thrombin	NN	B-NP
and	and	CC	0
plasmin	plasmin	NN	B-NP
by	by	IN	0
thrombin	thrombin	NN	B-NP
pai-1	pai-1	NN	I-NP
(	(	-LRB-	0
0.025	0.025	NNP	0
U	U	NNP	0
)	)	-RRB-	0
,	,	,	0
or	or	CC	0
plasmin	plasmin	NN	B-NP
(	(	-LRB-	0
0.1	0.1	CD	0
μg	μg	CD	B-NP
/	/	CD	I-NP
ml	ml	CD	I-NP
)	)	-RRB-	0
was	was	VBD	0
incubated	incubated	VBN	0
at	at	IN	0
37°C	37°C	CD	0
for	for	IN	0
30	30	CD	0
min	min	NN	B-NP
with	with	IN	0
same	same	JJ	0
amount	amount	NN	0
of	of	IN	0
wtPAI-1	wtPAI-1	NNP	B-NP
,	,	,	0
E351A	E351A	NNP	0
and	and	CC	0
E351R	E351R	CD	0
in	in	IN	0
term	term	NN	0
of	of	IN	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
toward	toward	IN	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
(	(	-LRB-	0
20	20	CD	0
U	U	NNP	0
in	in	IN	0
the	the	DT	0
concentration	concentration	NN	B-NP
range	range	NN	I-NP
of	of	IN	0
4-10	4-10	FW	0
μg	μg	NN	B-NP
/	/	NN	I-NP
ml	ml	NN	I-NP
)	)	-RRB-	0
in	in	IN	0
absence	absence	NN	B-NP
or	or	CC	0
presence	presence	NN	0
of	of	IN	0
vitronectin	vitronectin	NN	B-NP
(	(	-LRB-	0
60	60	CD	0
μg	μg	CD	B-NP
/	/	CD	I-NP
ml	ml	CD	I-NP
)	)	-RRB-	0
.	.	.	0
absorbance	absorbance	NN	B-NP
linear	linear	JJ	I-NP
increase	increase	NN	I-NP
at	at	IN	0
405	405	CD	0
nm	nm	NN	B-NP
were	were	VBD	0
recorded	recorded	VBN	0
after	after	IN	0
adding	adding	VBG	B-NP
S-2238	S-2238	NNP	I-NP
(	(	-LRB-	0
final	final	JJ	B-NP
concentration	concentration	NN	I-NP
0.25	0.25	CD	0
mM	mM	NN	0
)	)	-RRB-	0
for	for	IN	0
thrombin	thrombin	NN	B-NP
,	,	,	0
or	or	CC	0
N-p-Tosyl-Gly-Pro-Lys-p-Nitroanilide	N-p-Tosyl-Gly-Pro-Lys-p-Nitroanilide	NNP	B-NP
(	(	-LRB-	0
final	final	JJ	B-NP
concentration	concentration	NN	I-NP
0.5	0.5	CD	0
mM	mM	NN	0
)	)	-RRB-	0
for	for	IN	0
plasmin	plasmin	NN	B-NP
.	.	.	0
Thrombin	Thrombin	NNP	B-NP
,	,	,	0
or	or	CC	0
plasmin	plasmin	JJ	B-NP
activity	activity	NN	I-NP
without	without	IN	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
was	was	VBD	0
taken	taken	VBN	0
as	as	IN	0
100	100	CD	0
%	%	NN	0
.	.	.	0
pai-1	pai-1	NN	B-NP
neutralization	neutralization	NN	I-NP
by	by	IN	0
Thrombin	Thrombin	NNP	B-NP
wtPAI-1	wtPAI-1	NNP	I-NP
and	and	CC	0
mutant	mutant	NN	B-NP
were	were	VBD	0
incubated	incubated	VBN	0
with	with	IN	0
four	four	CD	0
thrombin	thrombin	NNS	B-NP
molar	molar	JJ	I-NP
excess	excess	NN	I-NP
(	(	-LRB-	0
40	40	CD	0
nM	nM	NN	B-NP
)	)	-RRB-	0
in	in	IN	0
the	the	DT	0
absence	absence	NN	B-NP
or	or	CC	0
presence	presence	NN	0
of	of	IN	0
vitronectin	vitronectin	NN	B-NP
(	(	-LRB-	0
30	30	CD	0
nM	nM	NN	B-NP
)	)	-RRB-	0
.	.	.	0
control	control	NN	B-NP
experiment	experiment	NN	I-NP
were	were	VBD	0
carried	carried	VBN	0
out	out	RP	0
in	in	IN	0
the	the	DT	0
thrombin	thrombin	NN	B-NP
absence	absence	NN	I-NP
.	.	.	0
After	After	IN	0
20	20	CD	0
min	min	NN	B-NP
at	at	IN	0
37°C	37°C	NNP	0
,	,	,	0
the	the	DT	0
activity	activity	NN	0
of	of	IN	0
thrombin	thrombin	NN	B-NP
was	was	VBD	0
quenched	quenched	VBN	0
by	by	IN	0
the	the	DT	0
hirudin	hirudin	NNS	B-NP
addition	addition	NN	I-NP
(	(	-LRB-	0
final	final	JJ	B-NP
concentration	concentration	NN	I-NP
,	,	,	0
60	60	CD	0
units	units	NNS	0
/	/	CD	0
ml	ml	CD	0
)	)	-RRB-	0
,	,	,	0
resulting	resulting	VBG	0
in	in	IN	0
inhibition	inhibition	NN	0
of	of	IN	0
more	more	JJR	0
than	than	IN	0
95	95	CD	0
%	%	NN	0
of	of	IN	0
the	the	DT	0
thrombin	thrombin	NN	B-NP
amidolytic	amidolytic	JJ	I-NP
activity	activity	NN	I-NP
.	.	.	0
Subsequently	Subsequently	RB	0
,	,	,	0
the	the	DT	0
inhibitory	inhibitory	JJ	B-NP
activity	activity	NN	I-NP
residual	residual	JJ	I-NP
pai-1	pai-1	NN	I-NP
was	was	VBD	0
determined	determined	VBN	0
by	by	IN	0
aliquot	aliquot	NN	B-NP
titration	titration	NN	I-NP
on	on	IN	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
,	,	,	0
using	using	VBG	0
S2444	S2444	NN	0
as	as	IN	0
substrate	substrate	NN	0
.	.	.	0
The	The	DT	0
increase	increase	NN	0
of	of	IN	0
the	the	DT	0
optical	optical	JJ	B-NP
density	density	NN	I-NP
at	at	IN	0
405	405	CD	0
nm	nm	NN	B-NP
in	in	IN	0
the	the	DT	0
samples	samples	NNS	0
was	was	VBD	0
corrected	corrected	VBN	0
for	for	IN	0
the	the	DT	0
values	values	NNS	0
measured	measured	VBN	0
with	with	IN	0
(	(	-LRB-	0
hirudin-inactivated	hirudin-inactivated	NNP	B-NP
)	)	-RRB-	0
thrombin	thrombin	VBZ	0
alone	alone	RB	0
,	,	,	0
since	since	IN	0
the	the	DT	0
thrombin	thrombin	NN	B-NP
amidolytic	amidolytic	JJ	I-NP
activity	activity	NN	I-NP
on	on	IN	0
S2444	S2444	NNP	0
was	was	VBD	0
not	not	RB	0
completely	completely	RB	0
blocked	blocked	VBN	0
by	by	IN	0
hirudin	hirudin	NN	B-NP
,	,	,	0
pai-1	pai-1	NN	B-NP
complex	complex	JJ	I-NP
formation	formation	NN	I-NP
with	with	IN	0
tPA	tPA	JJ	0
or	or	CC	0
fibrosarcoma	fibrosarcoma	JJ	B-NP
pai-1	pai-1	NN	I-NP
upa	upa	NN	I-NP
complex	complex	JJ	I-NP
formation	formation	NN	I-NP
,	,	,	0
wtPAI-1	wtPAI-1	NNP	B-NP
or	or	CC	0
its	its	PRP$	0
mutant	mutant	NN	B-NP
with	with	IN	0
single-chain	single-chain	JJ	B-NP
tPA	tPA	JJ	0
or	or	CC	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
were	were	VBD	0
performed	performed	VBN	0
as	as	RB	0
described	described	VBN	0
earlier	earlier	RBR	0
[	[	-LRB-	0
20	20	CD	0
]	]	-RRB-	0
.	.	.	0
Samples	Samples	NNS	0
of	of	IN	0
PAI-1s	PAI-1s	NNP	B-NP
(	(	-LRB-	0
5	5	CD	0
U	U	NNP	0
)	)	-RRB-	0
were	were	VBD	0
incubated	incubated	VBN	0
in	in	IN	0
the	the	DT	0
absence	absence	NN	B-NP
or	or	CC	0
in	in	IN	0
the	the	DT	0
presence	presence	NN	0
of	of	IN	0
a	a	DT	0
2-fold	2-fold	JJ	0
excess	excess	NN	0
of	of	IN	0
uPA	uPA	JJ	0
or	or	CC	0
tPA	tPA	JJ	0
in	in	IN	0
the	the	DT	0
activity	activity	NN	B-NP
assay	assay	NN	I-NP
buffer	buffer	NN	I-NP
.	.	.	0
Following	Following	VBG	0
a	a	DT	0
30	30	CD	0
min	min	JJ	B-NP
incubation	incubation	NN	I-NP
at	at	IN	0
room	room	NN	B-NP
temperature	temperature	NN	I-NP
,	,	,	0
the	the	DT	0
samples	samples	NNS	0
were	were	VBD	0
subjected	subjected	VBN	0
to	to	TO	0
a	a	DT	0
10	10	CD	0
%	%	NN	0
SDS-PAGE	SDS-PAGE	NN	B-NP
and	and	CC	0
immunoblotting	immunoblotting	VBP	0
as	as	RB	0
described	described	VBN	0
above	above	IN	0
.	.	.	0
type	type	NN	B-NP
plasminogen	plasminogen	NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
activator	activator	NN	I-NP
abbreviation	abbreviation	NN	I-NP
,	,	,	0
plasminogen	plasminogen	JJ	B-NP
activator	activator	NN	I-NP
tissue-type	tissue-type	JJ	I-NP
;	;	:	0
urokinase	urokinase	NN	B-NP
plasminogen	plasminogen	NN	I-NP
activator	activator	NN	I-NP
,	,	,	0
urokinase-type	urokinase-type	JJ	B-NP
plasminogen	plasminogen	JJ	I-NP
activator	activator	NN	I-NP
;	;	:	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
1	1	NN	I-NP
,	,	,	0
plasminogen	plasminogen	NN	B-NP
activator	activator	NN	I-NP
inhibitor	inhibitor	NN	I-NP
type	type	NN	I-NP
1	1	CD	0
;	;	:	0
serpin	serpin	CD	B-NP
,	,	,	0
serine	serine	NN	B-NP
protease	protease	NN	I-NP
inhibitor	inhibitor	NN	I-NP
;	;	:	0
RCL	RCL	NNP	B-NP
,	,	,	0
reactive	reactive	JJ	B-NP
center	center	NN	I-NP
loop	loop	NN	I-NP
;	;	:	0
Vn	Vn	NNP	B-NP
,	,	,	0
vitronectin	vitronectin	NN	B-NP
,	,	,	0
sd	sd	NN	B-NP
,	,	,	0
sodium	sodium	JJ	B-NP
dodecylsulfate	dodecylsulfate	NN	I-NP
;	;	:	0
PAGE	PAGE	NNP	0
,	,	,	0
polyacrylamide	polyacrylamide	NN	B-NP
gel	gel	NN	I-NP
electrophoresi	electrophoresi	NN	I-NP
.	.	.	0
guanidine	guanidine	NN	B-NP
hydrochloride	hydrochloride	NN	I-NP
,	,	,	0
guanidine-hydrochloride	guanidine-hydrochloride	JJ	B-NP
;	;	:	0
horseradish	horseradish	NN	B-NP
peroxidase	peroxidase	NN	I-NP
,	,	,	0
horseradish	horseradish	JJ	B-NP
peroxidase	peroxidase	NN	I-NP
;	;	:	0
enhanced	enhanced	VBN	B-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
chemiluminescence	chemiluminescence	NN	I-NP
,	,	,	0
enhanced	enhanced	JJ	0
chemiluminescence	chemiluminescence	NN	B-NP
;	;	:	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
,	,	,	0
phosphate-buffered	phosphate-buffered	JJ	B-NP
saline	saline	NN	I-NP
;	;	:	0
BSA	BSA	NNP	B-NP
,	,	,	0
bovine	bovine	JJ	B-NP
serum	serum	NN	I-NP
albumin	albumin	NN	I-NP
.	.	.	0
Authors	Authors	NNP	0
'	'	POS	0
contribution	contribution	NN	0
Qingcai	Qingcai	NNP	0
Wang	Wang	NNP	0
carried	carried	VBD	0
out	out	RP	0
the	the	DT	0
experiments	experiments	NNS	0
and	and	CC	0
drafted	drafted	VBD	0
the	the	DT	0
manuscript	manuscript	NN	0
;	;	:	0
Professor	Professor	NNP	B-NP
Shmuel	Shmuel	NNP	I-NP
Shaltiel	Shaltiel	NNP	I-NP
sponsored	sponsored	NN	I-NP
and	and	CC	0
supervised	supervised	VBD	0
the	the	DT	0
project	project	NN	B-NP
and	and	CC	0
revised	revised	VBN	0
the	the	DT	0
manuscript	manuscript	NN	0
.	.	.	0
